<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40865109</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2590-7379</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>11</Day></PubDate></JournalIssue><Title>Biomedica : revista del Instituto Nacional de Salud</Title><ISOAbbreviation>Biomedica</ISOAbbreviation></Journal><ArticleTitle>Prevalence and characterization of human immunodeficiency virus coinfection in patients hospitalized with tuberculosis in a reference hospital in Bogot&#xe1;.</ArticleTitle><Pagination><StartPage>423</StartPage><EndPage>435</EndPage><MedlinePgn>423-435</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7705/biomedica.7664</ELocationID><Abstract><AbstractText>Introducci&#xf3;n. La tuberculosis es la principal causa de muerte en los pacientes con infecci&#xf3;n por el virus de la inmunodeficiencia humana. La coinfecci&#xf3;n de Mycobacterium tuberculosis y HIV es muy frecuente. Objetivo. Establecer la prevalencia de la infecci&#xf3;n por HIV en pacientes hospitalizados con tuberculosis, y determinar sus caracter&#xed;sticas y desenlaces. Materiales y m&#xe9;todos. Se realiz&#xf3; un estudio retrospectivo, de corte transversal, en pacientes con tuberculosis -pulmonar o extrapulmonar- y coinfecci&#xf3;n por HIV, hospitalizados en una instituci&#xf3;n de referencia de Bogot&#xe1; entre el 2019 y el 2021. Resultados. En el grupo de los 102 pacientes con tuberculosis, la prevalencia de infecci&#xf3;n por HIV fue del 52,3% (54). Entre estos 54, 24 pacientes (44,4%) tuvieron confirmaci&#xf3;n microbiol&#xf3;gica o histopatol&#xf3;gica de la tuberculosis y, 19 (35,2 %), infecci&#xf3;n por VIH de novo. En los 54 coinfectados, la mediana de la edad fue de 38 a&#xf1;os (RIC: 29-42). El 79,6 % (43/54) fueron hombres. La mediana del n&#xfa;mero de linfocitos T CD4+ fue de 59 c&#xe9;lulas/&#x3bc;l (RIC: 32-120), y el 72,2 % (39/54) ten&#xed;a menos de 200 c&#xe9;lulas/&#x3bc;l. El 31,4 % (17/54) de los pacientes con antecedente de infecci&#xf3;n por HIV recib&#xed;a terapia antirretroviral. En cuanto a la forma cl&#xed;nica, la tuberculosis fue pulmonar en el 51,9 % (28/54) y extrapulmonar en el 48,1 % (26/54) de los pacientes. La tuberculosis extrapulmonar fue men&#xed;ngea (29,6 %), miliar (12,9 %), pleural (3,7 %) y peritoneal (3,7 %). Hubo 33,3 % de mortalidad intrahospitalaria, asociada con el n&#xfa;mero de linfocitos T CD4+ (p &lt; 0,05), el diagn&#xf3;stico de novo de HIV (p &lt; 0,04) y la presencia de tuberculosis men&#xed;ngea (p &lt; 0,03). Conclusi&#xf3;n. La coinfecci&#xf3;n de Mycobacterium tuberculosis y HIV es frecuente y se relaciona con una inmunosupresi&#xf3;n avanzada, por lo que debe hacerse una b&#xfa;squeda activa de la infecci&#xf3;n con HIV en estos casos. La tuberculosis men&#xed;ngea fue la forma extrapulmonar m&#xe1;s frecuente y se asoci&#xf3; con mortalidad.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Puentes-Ariza</LastName><ForeName>Gean Carlo</ForeName><Initials>GC</Initials><Identifier Source="ORCID">0000-0002-7001-1157</Identifier><AffiliationInfo><Affiliation>Departamento de Medicina Interna, Facultad de Medicina, Universidad Nacional de Colombia, Bogot&#xe1;, D. C., Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mel&#xe9;ndez-Rhenals</LastName><ForeName>Sugeich</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4593-3125</Identifier><AffiliationInfo><Affiliation>Departamento de Medicina Interna, Facultad de Medicina, Universidad Nacional de Colombia, Bogot&#xe1;, D. C., Colombia; Servicio de Medicina Interna, Hospital Universitario Nacional de Colombia, Corporaci&#xf3;n Salud UN, Bogot&#xe1;, D.C., Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nocua-B&#xe1;ez</LastName><ForeName>Laura Cristina</ForeName><Initials>LC</Initials><Identifier Source="ORCID">0000-0003-2869-2339</Identifier><AffiliationInfo><Affiliation>Departamento de Medicina Interna, Facultad de Medicina, Universidad Nacional de Colombia, Bogot&#xe1;, D. C., Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe1;ez-Ardila</LastName><ForeName>Hugo</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-4690-9055</Identifier><AffiliationInfo><Affiliation>Servicio de Infectolog&#xed;a, Hospital Sim&#xf3;n Bol&#xed;var, Bogot&#xe1;, D.C., Colombia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Prevalencia y caracterizaci&#xf3;n de la coinfecci&#xf3;n por el virus de la inmunodeficiencia humana en pacientes hospitalizados con tuberculosis en un hospital de referencia de Bogot&#xe1;.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Colombia</Country><MedlineTA>Biomedica</MedlineTA><NlmUniqueID>8205605</NlmUniqueID><ISSNLinking>0120-4157</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="Y">HIV Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060085" MajorTopicYN="Y">Coinfection</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014376" MajorTopicYN="Y">Tuberculosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003105" MajorTopicYN="N" Type="Geographic">Colombia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="eng"><AbstractText Label="INTRODUCTION.">Tuberculosis is the leading cause of death in patients with human immunodeficiency virus infection; tuberculosis-HIV coinfection is highly prevalent.</AbstractText><AbstractText Label="OBJECTIVE.">To establish the prevalence of HIV infection in patients hospitalized with tuberculosis and determine their characteristics and outcomes.</AbstractText><AbstractText Label="MATERIALS AND METHODS.">We conducted a retrospective cross-sectional study in patients diagnosed with pulmonary or extrapulmonary tuberculosis and HIV coinfection, hospitalized in a referral institution in Bogot&#xe1; between 2019 and 2021.</AbstractText><AbstractText Label="RESULTS.">The prevalence of HIV infection in 102 patients with tuberculosis was 52.3% (54/102). Among them, 24 patients (44.4%) had microbiological or histopathological confirmation of tuberculosis infection; and 19 (35.2%) were recently diagnosed with an HIV infection. The median age of the 54 coinfected patients was 38 years (IQR: 29-42); 79.6% (43/54) were men. The median CD4+ T-cell count was 59 cells/&#x3bc;L (IQR: 32-120), and 72.2% (39/54) had a CD4+ count of less than 200 cells/&#x3bc;L; 31.4% (17/54) of patients with a history of HIV infection were receiving antiretroviral therapy. Regarding tuberculosis clinical presentation, 51.9% (28/54) had pulmonary tuberculosis, and 48.1% (26/54) had extrapulmonary tuberculosis. The extrapulmonary tuberculosis forms were meningeal (29.6%), miliary (12.9%), pleural (3.7%), and peritoneal (3.7%). The in-hospital mortality was 33.3%, associated with a low CD4<sup>+</sup> count (p &lt; 0.05), recent HIV diagnosis (p &lt; 0.04), and the presence of meningeal tuberculosis (p &lt; 0.03).</AbstractText><AbstractText Label="CONCLUSION.">The frequency of tuberculosis-HIV coinfection is high and related to an advanced degree of immunosuppression. Therefore, we recommend an active search for coinfection. Meningeal tuberculosis was the most frequent extrapulmonary form and was associated with mortality.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">tuberculosis</Keyword><Keyword MajorTopicYN="N">pulmonary</Keyword><Keyword MajorTopicYN="N">HIV</Keyword><Keyword MajorTopicYN="N">opportunistic</Keyword><Keyword MajorTopicYN="N">infections</Keyword><Keyword MajorTopicYN="N">acquired</Keyword><Keyword MajorTopicYN="N">immunodeficiency</Keyword><Keyword MajorTopicYN="N">syndrome</Keyword></KeywordList><CoiStatement><b>Conflicto de intereses:</b> Los autores declaran no tener conflictos de intereses. </CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>28</Day><Hour>7</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>27</Day><Hour>20</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>27</Day><Hour>17</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40865109</ArticleId><ArticleId IdType="pmc">PMC12448568</ArticleId><ArticleId IdType="doi">10.7705/biomedica.7664</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Murray CJL, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(1005-70) doi: 10.1016/S0140-6736(14)60844-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)60844-8</ArticleId><ArticleId IdType="pmc">PMC4202387</ArticleId><ArticleId IdType="pubmed">25059949</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks SG, Overbaugh J, Phillips A, Buchbinder S. HIV infection. Nat Rev Dis Primers. 2015;1(15035) doi: 10.1038/nrdp.2015.35.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2015.35</ArticleId><ArticleId IdType="pubmed">27188527</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawlowski A, Jansson M, Sk&#xf6;ld M, Rottenberg ME, Kallenius G. Tuberculosis and HIV coinfection. PLoS Pathog. 2012;8(1002464) doi: 10.1371/joumal.ppat.1002464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/joumal.ppat.1002464</ArticleId><ArticleId IdType="pmc">PMC3280977</ArticleId><ArticleId IdType="pubmed">22363214</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO)   Global tuberculosis report 2024. Geneva: World Health Organization; 2024.  [18 de febrero de 2025].  Disponible en:  https://iris. who.int/bitstream/handle/10665/379339/9789240101531-eng.pdf?sequence=1
.</Citation></Reference><Reference><Citation>Letang E, Ellis J, Naidoo K, Casas EC, S&#xe1;nchez P, Hassan-Moosa R, et al. Tuberculosis- HIV co-infection: Progress and challenges after two decades of global antiretroviral treatment roll-out. Arch Bronconeumol. 2020;56:446&#x2013;454. doi: 10.1016/j.arbr.2019.11.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arbr.2019.11.013</ArticleId><ArticleId IdType="pubmed">35373756</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray JM, Cohn DL. Tuberculosis and HIV coinfection. Semin Respir Crit Care Med. 2013;34:32&#x2013;43. doi: 10.1055/s-0032-1333469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0032-1333469</ArticleId><ArticleId IdType="pubmed">23460004</ArticleId></ArticleIdList></Reference><Reference><Citation>Edge CL, King EJ, Dolan K, McKee M. Prisoners co-infected with tuberculosis and HIV: A systematic review. J Int AIDS Soc. 2016;19:20960&#x2013;20960. doi: 10.7448/IAS.19.1.20960.</Citation><ArticleIdList><ArticleId IdType="doi">10.7448/IAS.19.1.20960</ArticleId><ArticleId IdType="pmc">PMC5112354</ArticleId><ArticleId IdType="pubmed">27852420</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell LCK, Noursadeghi M. Pathogenesis of HIV-1 and Mycobacterium tuberculosis coinfection. Nat Rev Microbiol. 2018;16:80&#x2013;90. doi: 10.1038/nrmicro.2017.128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro.2017.128</ArticleId><ArticleId IdType="pubmed">29109555</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesfin YM, Hailemariam D, Biadgilign S, Kibret KT. Association between HIV/AIDS and multi-drug resistance tuberculosis: A systematic review and meta-analysis. PLoS ONE. 2013;8:e82235. doi: 10.1371/journal.pone.0082235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0082235</ArticleId><ArticleId IdType="pmc">PMC3885391</ArticleId><ArticleId IdType="pubmed">24416139</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockwood N, Wilkinson RJ. Understanding and intervening in HIV-associated tuberculosis. Clin Med (Lond) 2015;15(Suppl.6):S43&#x2013;S49. doi: 10.7861/clinmedicine.15-6-s43.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmedicine.15-6-s43</ArticleId><ArticleId IdType="pubmed">26634681</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadul-P&#xe9;rez S. Protocolo de Vigilancia de Tuberculosis.  [13de junio de 2024];Instituto Nacional de Salud. 2022 :1&#x2013;33. Disponible en:  https://www.ins.gov.co/buscador-eventos/Lineamientos/Pro_Tuberculosis%202022.pdf
.</Citation></Reference><Reference><Citation>Pan American Health Organization  . Factsheet 2022: TB/HIV co-infection in the Americas. Washington D. C.: PAHO/WHO; 2022.  [18 de febrero de 2025].  Disponible en:  https://www.paho.org/sites/default/files/2023-08/2022-cde-factsheet-tb-HIV-americas.pdf
.</Citation></Reference><Reference><Citation>Ministerio de Salud y Protecci&#xf3;n Social  . Lineamiento t&#xe9;cnico operativo del Programa Nacional de Tuberculosis. Direcci&#xf3;n de Promoci&#xf3;n y Prevenci&#xf3;n. Subdirecci&#xf3;n de Enfermedades Transmisibles. Bogot&#xe1;; D.C.: 2020.  [13 de junio de 2024].  Disponible en:  https://www.minsalud.gov.co/Normatividad_Nuevo/Resoluci%C3%B3n%20No.%20227%20de%202020.pdf 
.</Citation></Reference><Reference><Citation>StataCorp . Stata Statistical Software: Release 15. College Station. Texas: StataCorp; 2017.</Citation></Reference><Reference><Citation>Ministerio de Salud  . Resoluci&#xf3;n n&#xfa;mero 8430 de 1993 por la cual se establecen las normas cient&#xed;ficas, t&#xe9;cnicas y administrativas para la investigaci&#xf3;n en salud. 1993.  [13 de junio de 2024].  Disponible en:  https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/DE/DIJ/RESOLUCION-8430-DE-1993.pdf
.</Citation></Reference><Reference><Citation>Frieden TR, Harold Jaffe DW, Moran JS, Leahy MA, Martinroe JC, Spriggs SR, et al. Revised surveillance case definition for HIV Infection - United States, 2014. Vol. 63. MMWR Recomm Rep; 2014. pp. 1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">24717910</ArticleId></ArticleIdList></Reference><Reference><Citation>Joint United Nations Programme on HIV/AIDS (UNAIDS)   In danger: UNAIDS Global AIDS Update 2022. Geneva: UNAIDS; 2022.  [13 de junio de 2024].  Disponible en:  https://www.unaids.org/sites/default/files/media asset/2022-global-aids-update en.pdf
.</Citation></Reference><Reference><Citation>Kawatsu L, Uchimura K, Kaneko N, Imahashi M. Epidemiology of coinfection with tuberculosis and HIV in Japan, 2012-2020. West Pac Surveill Response J. 2022;13:1&#x2013;8. doi: 10.5365/wpsar.2022.13.1.896.</Citation><ArticleIdList><ArticleId IdType="doi">10.5365/wpsar.2022.13.1.896</ArticleId><ArticleId IdType="pmc">PMC9016268</ArticleId><ArticleId IdType="pubmed">35494412</ArticleId></ArticleIdList></Reference><Reference><Citation>Zohar M, Moshe L, Daniel C, Noa C, Itamar G. HIV prevalence in the Israeli tuberculosis cohort, 1999-2011. BMC Public Health. 2014;14:1090&#x2013;1090. doi: 10.1186/1471-2458-14-1090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-14-1090</ArticleId><ArticleId IdType="pmc">PMC4221682</ArticleId><ArticleId IdType="pubmed">25335562</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Regional Office for Europe, European Centre for Disease Prevention and Control  . HIV/AIDS surveillance in Europe 2024-2023 data. Copenhagen: WHO Regional Office for Europe; 2024.  [18 de febrero de 2025].  Disponible en:  https://www.ecdc.europa.eu/sites/default/files/documents/HIV_Surveillance_Report_2024.pdf
.</Citation></Reference><Reference><Citation>Cuenta de Alto Costo (CAC)   Situaci&#xf3;n del HIV en Colombia 2024. Bogot&#xe1;, D. C.: Fondo Colombiano de Enfermedades de Alto Costo; 2025.  [18 de febrero de 2025].  Disponible en:  https://cuentadealtocosto.org/publicaciones/situacion-del-HIV-en-colombia-2024/
</Citation></Reference><Reference><Citation>Cort&#xe9;s JA, Hidalgo P, Rey DL, Parra GA, Guti&#xe9;rrez IF. Tuberculosis en pacientes con infecci&#xf3;n por VIH en el Hospital Universitario de San Ignacio, 2002-2006. Infectio. 2007;11:16&#x2013;22.</Citation></Reference><Reference><Citation>Ruiz L, Maya MA, Rueda ZV, L&#xf3;pez L, V&#xe9;lez LA. Current characteristics of tuberculosis and human immunodeficiency virus co-infection in a cohort of hospitalized patients in Medell&#xed;n, Colombia. Biom&#xe9;dica. 2018;38:59&#x2013;67. doi: 10.7705/biomedica.v38i3.3862.</Citation><ArticleIdList><ArticleId IdType="doi">10.7705/biomedica.v38i3.3862</ArticleId><ArticleId IdType="pubmed">30184364</ArticleId></ArticleIdList></Reference><Reference><Citation>Tancredi MV, Sakabe S, Waldman EA. Mortality and survival of tuberculosis coinfected patients living with AIDS in S&#xe3;o Paulo, Brazil: A 12-year cohort study. BMC Infect Dis. 2022;22:223&#x2013;223. doi: 10.1186/s12879-022-07232-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07232-6</ArticleId><ArticleId IdType="pmc">PMC8897065</ArticleId><ArticleId IdType="pubmed">35246066</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanhueza-Sanzana C, Kerr L, Kendall C. Mortality from AIDS and tuberculosis- HIV coinfection in the Chilean AIDS Cohort of 2000-2017. Cad Sa&#xfa;de P&#xfa;blica. 2021;37:e00212920. doi: 10.1590/0102-311X00212920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/0102-311X00212920</ArticleId><ArticleId IdType="pubmed">34190832</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a I, Merch&#xe1;n A, Chaparro PE, L&#xf3;pez LE. Panorama de la coinfecci&#xf3;n tuberculosis/HIV en Bogot&#xe1;, 2001. Biom&#xe9;dica. 2004;24(Supl.1):132&#x2013;137. doi: 10.7705/biomedica.v24iSupp1.1312.</Citation><ArticleIdList><ArticleId IdType="doi">10.7705/biomedica.v24iSupp1.1312</ArticleId><ArticleId IdType="pubmed">15495581</ArticleId></ArticleIdList></Reference><Reference><Citation>Mont&#xfa;far Andrade FE, Villa Franco P, Mont&#xfa;far Pantoja MC, Zuleta Tob&#xf3;n JJ, P&#xe9;rez Jaramillo LE, Monsalve Valencia MA, et al. Coinfecci&#xf3;n por virus de inmunodeficiencia humana y micobacterias en un hospital universitario de alta complejidad en Colombia. Infectio. 2016;20:158&#x2013;164. doi: 10.1016/j.infect.2015.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.infect.2015.05.004</ArticleId></ArticleIdList></Reference><Reference><Citation>Joint United Nations Programme on HIV/AIDS (UNAIDS)  Global HIV &amp; AIDS statistics - Fact sheet 2024. Geneva: UNAIDS; 2024.  [19 de febrero de 2025].  Disponible en:   https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf 
.</Citation></Reference><Reference><Citation>de Vries G, van de Berg S, van Dam A, Hasanova S, Pareek M, van der Werf MJ, et al. Collaborative tuberculosis/HIV activities in the European Region. ERJ Open Res. 2021;7:00721&#x2013;02020. doi: 10.1183/23120541.00721-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00721-2020</ArticleId><ArticleId IdType="pmc">PMC7836583</ArticleId><ArticleId IdType="pubmed">33532469</ArticleId></ArticleIdList></Reference><Reference><Citation>Abay SM, Deribe K, Reda AA, Biadgilign S, Datiko D, Assefa T, et al. The Effect of early initiation of antiretroviral therapy in TB/HIV-coinfected patients: A systematic review and meta-analysis. J Int Assoc Provid AIDS Care. 2015;14:560&#x2013;570. doi: 10.1177/2325957415599210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2325957415599210</ArticleId><ArticleId IdType="pubmed">26289343</ArticleId></ArticleIdList></Reference><Reference><Citation>Plata-Casas L, Guti&#xe9;rrez-Lesmes O, Herr&#xe1;n-Falla O. Infecci&#xf3;n concomitante por tuberculosis y el virus de la inmunodeficiencia humana: situaci&#xf3;n epidemiol&#xf3;gica en el departamento del Meta, 2010-2015. Biom&#xe9;dica. 2018;38:68&#x2013;79. doi: 10.7705/biomedica.v38i3.3930.</Citation><ArticleIdList><ArticleId IdType="doi">10.7705/biomedica.v38i3.3930</ArticleId><ArticleId IdType="pubmed">30184365</ArticleId></ArticleIdList></Reference><Reference><Citation>Rindi L. Rapid molecular diagnosis of extra-pulmonary tuberculosis by Xpert/RIF ultra. Front Microbiol. 2022;13:817661&#x2013;817661. doi: 10.3389/fmicb.2022.817661.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.817661</ArticleId><ArticleId IdType="pmc">PMC9130774</ArticleId><ArticleId IdType="pubmed">35633667</ArticleId></ArticleIdList></Reference><Reference><Citation>Seddon JA, Tugume L, Solomons R, Prasad K, Bahr NC. Tuberculous Meningitis International Research Consortium. The current global situation for tuberculous meningitis: Epidemiology, diagnostics, treatment and outcomes. Wellcome Open Res. 2019;4:167&#x2013;167. doi: 10.12688/wellcomeopenres.15535.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/wellcomeopenres.15535.1</ArticleId><ArticleId IdType="pmc">PMC7029758</ArticleId><ArticleId IdType="pubmed">32118118</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecchini D, Ambrosioni J, Brezzo C, Corti M, Rybko A, P&#xe9;rez M, et al. Tuberculous meningitis in HIV-infected and non-infected patients: Comparison of cerebrospinal fluid findings. Int J Tuberc Lung Dis. 2009;13:269&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">19146759</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39122242</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Artificial Intelligence Imaging Diagnosis Using Super-Resolution and Three-Dimensional Shape for Lymph Node Metastasis of Low Rectal Cancer: A Pilot Study From a Single Center.</ArticleTitle><Pagination><StartPage>1131</StartPage><EndPage>1138</EndPage><MedlinePgn>1131-1138</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003381</ELocationID><Abstract><AbstractText Label="BACKGROUND">Although accurate preoperative diagnosis of lymph node metastasis is essential for optimizing treatment strategies for low rectal cancer, the accuracy of present diagnostic modalities has room for improvement.</AbstractText><AbstractText Label="OBJECTIVE">The study aimed to establish a high-precision diagnostic method for lymph node metastasis of low rectal cancer using artificial intelligence.</AbstractText><AbstractText Label="DESIGN">A retrospective observational study.</AbstractText><AbstractText Label="SETTINGS">A single cancer center and a college of engineering in Japan.</AbstractText><AbstractText Label="PATIENTS">Patients with low rectal adenocarcinoma who underwent proctectomy, bilateral lateral pelvic lymph node dissection, and contrast-enhanced multidetector row CT (slice &#x2264;1&#x2009;mm) between July 2015 and August 2021 were included in the present study. All pelvic lymph nodes from the aortic bifurcation to the upper edge of the anal canal were extracted, regardless of whether within or beyond the total mesenteric excision area, and pathological diagnoses were annotated for training and validation.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy.</AbstractText><AbstractText Label="RESULTS">A total of 596 pathologically negative nodes and 43 positive nodes from 52 patients were extracted and annotated. Four diagnostic methods, with and without using super-resolution images and with and without using 3-dimensional shape data, were performed and compared. The super-resolution + 3-dimensional shape data method had the best diagnostic ability for the combination of sensitivity, negative predictive value, and accuracy (0.964, 0.966, and 0.968, respectively), whereas the super-resolution only method had the best diagnostic ability for the combination of specificity and positive predictive value (0.994 and 0.993, respectively).</AbstractText><AbstractText Label="LIMITATIONS">Small number of patients at a single center and the lack of external validation.</AbstractText><AbstractText Label="CONCLUSIONS">Our results enlightened the potential of artificial intelligence for the method to become another game changer in the diagnosis and treatment of low rectal cancer. See Video Abstract .</AbstractText><AbstractText Label="DIAGNSTICO POR IMGENES CON INTELIGENCIA ARTIFICIAL MEDIANTE SUPERRESOLUCIN Y FORMA D PARA LA METSTASIS EN LOS GANGLIOS LINFTICOS DEL CNCER DE RECTO BAJO UN ESTUDIO PILOTO DE UN SOLO CENTRO">ANTECEDENTES:Aunque el diagn&#xf3;stico preoperatorio preciso de met&#xe1;stasis en los ganglios linf&#xe1;ticos es esencial para optimizar las estrategias de tratamiento para el c&#xe1;ncer de recto bajo, la precisi&#xf3;n de las modalidades de diagn&#xf3;stico actuales tiene margen de mejora.OBJETIVO:Establecer un m&#xe9;todo de diagn&#xf3;stico de alta precisi&#xf3;n para las met&#xe1;stasis en los ganglios linf&#xe1;ticos del c&#xe1;ncer de recto bajo utilizando inteligencia artificial.DISE&#xd1;O:Un estudio observacional retrospectivo.AJUSTE:Un &#xfa;nico centro oncol&#xf3;gico y una facultad de ingenier&#xed;a en Jap&#xf3;n.PACIENTES:En el presente estudio se incluyeron pacientes con adenocarcinoma rectal bajo sometidos a proctectom&#xed;a, disecci&#xf3;n bilateral de ganglios linf&#xe1;ticos p&#xe9;lvicos laterales y tomograf&#xed;a computarizada con m&#xfa;ltiples detectores con contraste (corte &#x2264;1&#x2009;mm) entre julio de 2015 y agosto de 2021. Se resecaron todos los ganglios linf&#xe1;ticos p&#xe9;lvicos desde la bifurcaci&#xf3;n a&#xf3;rtica hasta el borde superior del canal anal, independientemente de si estaban dentro o m&#xe1;s all&#xe1; del &#xe1;rea de escisi&#xf3;n mesent&#xe9;rica total, y se registraron los diagn&#xf3;sticos patol&#xf3;gicos para entrenamiento y validaci&#xf3;n.PRINCIPALES MEDIDAS DE RESULTADO:Sensibilidad, especificidad, valor predictivo positivo, valor predictivo negativo y precisi&#xf3;n.RESULTADOS:Se extrajeron y registraron un total de 596 ganglios patol&#xf3;gicamente negativos y 43 positivos de 52 pacientes. Se realizaron y compararon cuatro m&#xe9;todos de diagn&#xf3;stico, con y sin im&#xe1;genes de s&#xfa;per resoluci&#xf3;n y sin datos de imagen en 3D. El m&#xe9;todo de superresoluci&#xf3;n + datos de imagen en 3D tuvo la mejor capacidad de diagn&#xf3;stico para la combinaci&#xf3;n de sensibilidad, valor predictivo negativo y precisi&#xf3;n (0,964, 0,966 y 0,968, respectivamente), mientras que el m&#xe9;todo de s&#xfa;per resoluci&#xf3;n solo tuvo la mejor capacidad de diagn&#xf3;stico para la combinaci&#xf3;n de especificidad y valor predictivo positivo (0,994 y 0,993, respectivamente).LIMITACIONES:Peque&#xf1;o n&#xfa;mero de pacientes en un solo centro y falta de validaci&#xf3;n externa.CONCLUSIONES:Nuestros resultados iluminan el potencial de la inteligencia artificial para que el m&#xe9;todo se convierta en otro elemento de cambio en el diagn&#xf3;stico y tratamiento del c&#xe1;ncer de recto bajo. (Traducci&#xf3;n ---Dr. Fidel Ruiz Healy ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ouchi</LastName><ForeName>Akira</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0435-5370</Identifier><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwahori</LastName><ForeName>Yuji</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Computer Science, College of Engineering, Chubu University, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Kosuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Engineering, Nagoya Institute of Technology, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Funahashi</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Engineering, Nagoya Institute of Technology, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukui</LastName><ForeName>Shinji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Information Education, Aichi University of Education, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Komori</LastName><ForeName>Koji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kinoshita</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Aichi, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Aichi, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>#20K11873</GrantID><Agency>Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research (C)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008207" MajorTopicYN="Y">Lymphatic Metastasis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001185" MajorTopicYN="Y">Artificial Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008198" MajorTopicYN="Y">Lymph Nodes</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000230" MajorTopicYN="Y">Adenocarcinoma</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078542" MajorTopicYN="N">Proctectomy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021621" MajorTopicYN="N">Imaging, Three-Dimensional</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008197" MajorTopicYN="N">Lymph Node Excision</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061330" MajorTopicYN="N">Multidetector Computed Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010388" MajorTopicYN="N">Pelvis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>10</Day><Hour>15</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>10</Day><Hour>15</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>9</Day><Hour>19</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39122242</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003381</ArticleId><ArticleId IdType="pii">00003453-202409000-00007</ArticleId></ArticleIdList><ReferenceList><Title/><Reference><Citation>Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery&#x2014;the clue to pelvic recurrence? Br J Surg. 1982;69:613&#x2013;616.</Citation></Reference><Reference><Citation>Cedermark B, Dahlberg M, Glimelius B, P&#xe5;hlman L, Rutqvist LE, Wilking N; Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336:980&#x2013;987.</Citation></Reference><Reference><Citation>Kapiteijn E, Marijnen CA, Nagtegaal ID, et al.; Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638&#x2013;646.</Citation></Reference><Reference><Citation>Sauer R, Becker H, Hohenberger W, et al.; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731&#x2013;1740.</Citation></Reference><Reference><Citation>Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373:811&#x2013;820.</Citation></Reference><Reference><Citation>Cisel B, Pietrzak L, Michalski W, et al.; Polish Colorectal Study Group. Long-course preoperative chemoradiation versus 5&#x2009;&#xd7;&#x2009;5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol. 2019;30:1298&#x2013;1303.</Citation></Reference><Reference><Citation>Bahadoer RR, Dijkstra EA, van Etten B, et al.; RAPIDO collaborative investigators. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29&#x2013;42.</Citation></Reference><Reference><Citation>Conroy T, Bosset JF, Etienne PL, et al.; Unicancer Gastrointestinal Group and Partenariat de Recherche en Oncologie Digestive (PRODIGE) Group. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702&#x2013;715.</Citation></Reference><Reference><Citation>Jin J, Tang Y, Hu C, et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol. 2022;40:1681&#x2013;1692.</Citation></Reference><Reference><Citation>Fujita S, Mizusawa J, Kanemitsu Y, et al.; Colorectal Cancer Study Group of Japan Clinical Oncology Group. Mesorectal excision with or without lateral lymph node dissection for clinical stage II/III lower rectal cancer (JCOG0212): a multicenter, randomized controlled, noninferiority trial. Ann Surg. 2017;266:201&#x2013;207.</Citation></Reference><Reference><Citation>Hojo K, Koyama Y, Moriya Y. Lymphatic spread and its prognostic value in patients with rectal cancer. Am J Surg. 1982;144:350&#x2013;354.</Citation></Reference><Reference><Citation>Moriya Y, Sugihara K, Akasu T, Fujita S. Nerve-sparing surgery with lateral node dissection for advanced lower rectal cancer. Eur J Cancer. 1995;31:1229&#x2013;1232.</Citation></Reference><Reference><Citation>Sugihara K, Kobayashi H, Kato T, et al. Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis Colon Rectum. 2006;49:1663&#x2013;1672.</Citation></Reference><Reference><Citation>Akiyoshi T, Watanabe T, Miyata S, Kotake K, Muto T, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Results of a Japanese nationwide multi-institutional study on lateral pelvic lymph node metastasis in low rectal cancer: is it regional or distant disease? Ann Surg. 2012;255:1129&#x2013;1134.</Citation></Reference><Reference><Citation>Emile SH, Horesh N, Freund MR, et al. Trends in the characteristics, treatment, and outcomes of rectal adenocarcinoma in the US from 2004 to 2019: a national cancer database analysis. JAMA Oncol. 2023;9:355&#x2013;364.</Citation></Reference><Reference><Citation>Al-Sukhni E, Milot L, Fruitman M, et al. Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol. 2012;19:2212&#x2013;2223.</Citation></Reference><Reference><Citation>Park JS, Jang YJ, Choi GS, et al. Accuracy of preoperative MRI in predicting pathology stage in rectal cancers: node-for-node matched histopathology validation of MRI features. Dis Colon Rectum. 2014;57:32&#x2013;38.</Citation></Reference><Reference><Citation>Li XT, Sun YS, Tang L, Cao K, Zhang XY. Evaluating local lymph node metastasis with magnetic resonance imaging, endoluminal ultrasound and computed tomography in rectal cancer: a meta-analysis. Colorectal Dis. 2015;17:O129&#x2013;O135.</Citation></Reference><Reference><Citation>Glynne-Jones R, Wyrwicz L, Tiret E, et al.; ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv22&#x2013;iv40.</Citation></Reference><Reference><Citation>Nicholls RJ, Zinicola R, Haboubi N. Extramural spread of rectal cancer and the AJCC Cancer Staging Manual 8th edition, 2017. Ann Oncol. 2019;30:1394&#x2013;1395.</Citation></Reference><Reference><Citation>Benson AB, Venook AP, Al-Hawary MM, et al. NCCN guidelines insights: rectal cancer, version 6.2020. J Natl Compr Canc Netw. 2020;18:806&#x2013;815.</Citation></Reference><Reference><Citation>Zhuang Z, Zhang Y, Wei M, Yang X, Wang Z. Magnetic resonance imaging evaluation of the accuracy of various lymph node staging criteria in rectal cancer: a systematic review and meta-analysis. Front Oncol. 2021;11:709070.</Citation></Reference><Reference><Citation>Lu Y, Yu Q, Gao Y, et al. Identification of metastatic lymph nodes in MR imaging with faster region-based convolutional neural networks. Cancer Res. 2018;78:5135&#x2013;5143.</Citation></Reference><Reference><Citation>Jin L, Peng W, Yanzhao L, Yang Z, Xiaolong L, Kuan L. Transfer learning of pre- trained inception-v3 model for colorectal cancer lymph node metastasis classification. In: 2018 IEEE International Conference on Mechatronics and Automation (ICMA); August 1, 2018; Changchun, China.</Citation></Reference><Reference><Citation>Ozaki K, Kurose Y, Kawai K, et al. Development of a diagnostic artificial intelligence tool for lateral lymph node metastasis in advanced rectal cancer. Dis Colon Rectum. 2023;66:e1246&#x2013;e1253.</Citation></Reference><Reference><Citation>Fedorov A, Beichel R, Kalpathy-Cramer J, et al. 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging. 2012;30:1323&#x2013;1341.</Citation></Reference><Reference><Citation>Heijnen LA, Lambregts DM, Mondal D, et al. Diffusion-weighted MR imaging in primary rectal cancer staging demonstrates but does not characterise lymph nodes. Eur Radiol. 2013;23:3354&#x2013;3360.</Citation></Reference><Reference><Citation>Yu J, Dai X, Zou HH, et al. Diffusion kurtosis imaging in identifying the malignancy of lymph nodes during the primary staging of rectal cancer. Colorectal Dis. 2018;20:116&#x2013;125.</Citation></Reference><Reference><Citation>Yu XP, Wen L, Hou J, Wang H, Lu Q. Discrimination of metastatic from non-metastatic mesorectal lymph nodes in rectal cancer using quantitative dynamic contrast-enhanced magnetic resonance imaging. J Huazhong Univ Sci Technolog Med Sci. 2016;36:594&#x2013;600.</Citation></Reference><Reference><Citation>Nakao T, Shimada M, Yoshikawa K, et al. Computed tomography texture analysis for the prediction of lateral pelvic lymph node metastasis of rectal cancer. World J Surg Oncol. 2022;20:281.</Citation></Reference><Reference><Citation>Sato K, Morohashi H, Tsushima F, et al. Dual energy CT is useful for the prediction of mesenteric and lateral pelvic lymph node metastasis in rectal cancer. Mol Clin Oncol. 2019;10:625&#x2013;630.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39087688</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>11</Issue><PubDate><Year>2024</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Comparative Study of Diluted Hydrogen Peroxide and Sulfur Hexafluoride in the Contrast-Enhanced Ultrasound Assessment of Anal Fistulas.</ArticleTitle><Pagination><StartPage>1450</StartPage><EndPage>1457</EndPage><MedlinePgn>1450-1457</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003445</ELocationID><Abstract><AbstractText Label="BACKGROUND">Endoanal ultrasound for the diagnosis of anal fistulas requires the injection of hydrogen peroxide, but it is often uncomfortable for the patient and has the potential to cause complications. Novel ultrasound contrast is currently available.</AbstractText><AbstractText Label="OBJECTIVE">To assess the efficacy and safety of sulfur hexafluoride as an ultrasound contrast agent for the diagnosis of a perianal fistula by comparing it with those of 50% diluted hydrogen peroxide.</AbstractText><AbstractText Label="DESIGN">Double-blinded superiority study with 4 consecutive visits to perform an ultrasound without contrast, a hydrogen peroxide-enhanced ultrasound, a sulfur hexafluoride-enhanced ultrasound, and a rectal exploration in the operating room (the criterion standard). The 3 expert surgeon sonographers independently reviewed the ultrasound images.</AbstractText><AbstractText Label="SETTING">This study was conducted at a single university hospital.</AbstractText><AbstractText Label="PATIENTS">Data from 176 patients were evaluated.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Demographic and exploratory data and the ultrasound findings related to the location of the internal fistula orifice, description of the primary and secondary tracts, and presence of cavities and sphincter defects were analyzed. Complications occurring before and after the contrast agent administration and pain score measured using a visual analog scale were considered.</AbstractText><AbstractText Label="RESULTS">Eighty-eight patients were included (men: 71.5%; mean age: 48.3 years), with 62.5% having a complex type fistula and 83.7% having a transsphincteric type fistula. Sulfur hexafluoride-enhanced ultrasounds demonstrated a higher interobserver agreement in determining the secondary tracts (&#x3ba; = 0.604) and anal fistula height (&#x3ba; = 0.604) compared with other methods. Both hydrogen peroxide-enhanced ultrasound (90.91%) and sulfur hexafluoride-enhanced ultrasound (89.77%) detected the internal orifice more frequently than ultrasounds without contrast (62.5%; p &lt; 0.001), with no differences between contrast agents ( p = 0.810). Sulfur hexafluoride-enhanced ultrasound was less painful than peroxide-enhanced ultrasound ( p &lt; 0.001).</AbstractText><AbstractText Label="LIMITATIONS">Most of the patients had transsphincteric anal fistulas.</AbstractText><AbstractText Label="CONCLUSIONS">Sulfur hexafluoride proved comparable to hydrogen peroxide in evaluating fistulous tracts and identifying the internal orifice, and it significantly reduced pain and discomfort. Furthermore, it demonstrated a higher interobserver agreement in determining the secondary tracts and anal fistula height compared with other methods. See Video Abstract .</AbstractText><AbstractText Label="ESTUDIO COMPARATIVO DE PERXIDO DE HIDRGENO DILUIDO Y HEXAFLUORURO DE AZUFRE EN LA EVALUACIN ECOGRFICA CON CONTRASTE DE FSTULAS ANALES">ANTECEDENTES:La ecograf&#xed;a endoanal para el diagn&#xf3;stico de f&#xed;stulas anales requiere la inyecci&#xf3;n de per&#xf3;xido de hidr&#xf3;geno, pero generalmente resulta inc&#xf3;moda para el paciente y presenta potenciales complicaciones. Actualmente se encuentran disponibles nuevos contrastes ecogr&#xe1;ficos.OBJETIVO:Evaluar la eficacia y seguridad del hexafluoruro de azufre como agente de contraste ecogr&#xe1;fico para el diagn&#xf3;stico de f&#xed;stula perianal compar&#xe1;ndolo con el per&#xf3;xido de hidr&#xf3;geno diluido al 50%.DISE&#xd1;O:Estudio de superioridad doble ciego con cuatro visitas consecutivas realizando una ecograf&#xed;a sin contraste, ecograf&#xed;a potenciada con per&#xf3;xido de hidr&#xf3;geno, ecograf&#xed;a potenciada con hexafluoruro de azufre y exploraci&#xf3;n rectal en el quir&#xf3;fano (el est&#xe1;ndar de oro). Las im&#xe1;genes ecogr&#xe1;ficas fueron revisadas de forma independiente por tres cirujanos ecografistas expertos.AJUSTE:Estudio llevado a cabo en un &#xfa;nico hospital universitario.PACIENTES:Se evaluaron datos de 176 pacientes.PRINCIPALES MEDIDAS DE RESULTADO:Se analizaron los datos demogr&#xe1;ficos y exploratorios y los hallazgos ecogr&#xe1;ficos relacionados con la ubicaci&#xf3;n del orificio interno de la f&#xed;stula, descripci&#xf3;n de los trayectos primario y secundario y la presencia de cavidades y defectos del esf&#xed;nter. Se consideraron las complicaciones ocurridas antes y despu&#xe9;s de la administraci&#xf3;n del agente de contraste y la presencia de dolor medido mediante un puntaje.RESULTADOS:Se incluyeron 88 pacientes (hombres: 71,5%; edad media: 48,3 a&#xf1;os). El 62,5% fueron tipo complejo y el 83,7% tipo transesfint&#xe9;rico. Las ecograf&#xed;as mejoradas con hexafluoruro de azufre demostraron mayor concordancia interobservador en la determinaci&#xf3;n de los trayectos secundarios (&#x3ba; = 0,604) y la altura de la f&#xed;stula anal (&#x3ba; = 0,604) en comparaci&#xf3;n con otros m&#xe9;todos. Tanto la ecograf&#xed;a con per&#xf3;xido de hidr&#xf3;geno (90,91%) como la ecograf&#xed;a con hexafluoruro de azufre (89,77%) detectaron con mayor frecuencia el orificio interno que la ecograf&#xed;a sin contraste (62,5%) (p &lt; 0,001), sin diferencias entre agentes de contraste (p = 0,810). La ecograf&#xed;a potenciada con hexafluoruro de azufre fue menos dolorosa que la ecograf&#xed;a potenciada con per&#xf3;xido (p &lt; 0,001).LIMITACIONES:La mayor&#xed;a de los pacientes presentaron f&#xed;stulas anales transesfint&#xe9;ricas.CONCLUSIONES:El hexafluoruro de azufre demostr&#xf3; ser comparable al per&#xf3;xido de hidr&#xf3;geno en la evaluaci&#xf3;n de los trayectos fistulosos y la identificaci&#xf3;n del orificio interno y con reducci&#xf3;n significativa del dolor y malestar. Adem&#xe1;s, demostr&#xf3; mayor concordancia interobservador en la determinaci&#xf3;n de los trayectos secundarios y la altura de la f&#xed;stula anal en comparaci&#xf3;n con otros m&#xe9;todos. (Traducci&#xf3;n-Dr. Fidel Ruiz Healy ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de la Portilla de Juan</LastName><ForeName>Fernando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Colorectal Unit, Department of General and Digestive Surgery, University Hospital Virgen del Roc&#xed;o, Seville University. Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Le&#xf3;n</LastName><ForeName>Anabel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of General and Digestive Surgery, University Hospital Virgen del Roc&#xed;o, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-S&#xe1;nchez</LastName><ForeName>Carlos Javier</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of General and Digestive Surgery, University Hospital Virgen del Roc&#xed;o, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mar&#xed;n</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of General and Digestive Surgery, Colorectal Unit, University Hospital Virgen del Roc&#xed;o, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reyes-D&#xed;az</LastName><ForeName>Mar&#xed;a L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of General and Digestive Surgery, Colorectal Unit, University Hospital Virgen del Roc&#xed;o, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>V&#xe1;zquez-Monchul</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General and Digestive Surgery, Colorectal Unit, University Hospital Virgen del Roc&#xed;o, Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padillo Ruiz</LastName><ForeName>Francisco J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Department of General and Digestive Surgery, University Hospital Virgen del Roc&#xed;o, Seville University. Seville, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003287">Contrast Media</NameOfSubstance></Chemical><Chemical><RegistryNumber>WS7LR3I1D6</RegistryNumber><NameOfSubstance UI="D013459">Sulfur Hexafluoride</NameOfSubstance></Chemical><Chemical><RegistryNumber>BBX060AN9V</RegistryNumber><NameOfSubstance UI="D006861">Hydrogen Peroxide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012003" MajorTopicYN="Y">Rectal Fistula</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003287" MajorTopicYN="Y">Contrast Media</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013459" MajorTopicYN="Y">Sulfur Hexafluoride</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006861" MajorTopicYN="Y">Hydrogen Peroxide</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019160" MajorTopicYN="N">Endosonography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014463" MajorTopicYN="N">Ultrasonography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001003" MajorTopicYN="N">Anal Canal</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>4</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>1</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>1</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39087688</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003445</ArticleId><ArticleId IdType="pii">00003453-202411000-00013</ArticleId></ArticleIdList><ReferenceList><Title/><Reference><Citation>Parks AG, Gordon PH, Hardcastle JE. A classification of fistula-in-ano. Br J Surg. 1976;63:1&#x2013;12.</Citation></Reference><Reference><Citation>Schwartz DA, Wiersema MJ, Dudiak KM, et al. A comparison of endoscopic ultrasound, magnetic resonance imaging, and exam under anesthesia for evaluation of Crohn&#x2019;s perianal fistulas. Gastroenterology. 2001;121:1064&#x2013;1072.</Citation></Reference><Reference><Citation>De la Portilla F, Al&#xf3;s R, Solana A, et al. Usefulness of anorectal ultrasounds in perianal Crohn&#x2019;s disease. Cir Esp. 2001;69:459&#x2013;462.</Citation></Reference><Reference><Citation>Sloots CE, Felt-Bersma RJ, Poen AC, Cuesta MA, Meuwissen SG. Assessment and classification of fistula-in-ano in patients with Crohn&#x2019;s disease by hydrogen peroxide enhanced transanal ultrasound. Int J Colorectal Dis. 2001;16:292&#x2013;297.</Citation></Reference><Reference><Citation>Van Bodegraven AA, Sloots CE, Felt-Bersma RJ, et al. Endosonographic evidence of persistence of Crohn&#x2019;s disease-associated fistulas after infliximab treatment, irrespective of clinical response. Dis Colon Rectum. 2001;45:39&#x2013;45.</Citation></Reference><Reference><Citation>De la Portilla F, Le&#xf3;n-Jim&#xe9;nez E, Cisneros N, et al. Use of anorectal ultrasounds in perianal Crohn&#x2019;s disease: consistency with clinical data. Rev Esp Enferm Dig. 2006;98:747&#x2013;754.</Citation></Reference><Reference><Citation>Siddiqui MRS, Ashrafian H, Tozer P, et al. A diagnostic accuracy meta-analysis of endoanal ultrasound and MRI for perianal fistula assessment. Dis Colon Rectum. 2012;55:576&#x2013;585.</Citation></Reference><Reference><Citation>Choen S, Burnett S, Bartram CI, Nicholls RJ. Comparison between anal endosonography and digital examination in the evaluation of anal fistulae. Br J Surg. 1991;78:445&#x2013;447.</Citation></Reference><Reference><Citation>Kim Y, Jin Park Y. Three-dimensional endoanal ultrasonographic assessment of an anal fistula with and without H 2 O 2 enhancement. World J Gastroenterol. 2009;15:4810&#x2013;4815.</Citation></Reference><Reference><Citation>Tsai SK, Lee TY, Mok MS. Gas embolism produced by hydrogen peroxide irrigation of an anal fistula during anesthesia. Anesthesiology. 1985;63:316&#x2013;317.</Citation></Reference><Reference><Citation>Kiran S, Marwah S, Bansal T, Gupta N. Venous air/oxygen embolism due to hydrogen peroxide in anal fistulectomy. J Anaesthesiol Clin Pharmacol. 2018;34:555&#x2013;557.</Citation></Reference><Reference><Citation>Schwab C, Dilworth K. Gas embolism produced by hydrogen peroxide abscess irrigation in an infant. Anaesth Intensive Care. 1999;27:418&#x2013;420.</Citation></Reference><Reference><Citation>Jones PM, Segal SH, Gelb AW. Venous oxygen embolism produced by injection of hydrogen peroxide into an enterocutaneous fistula. Anesth Analg. 2004;99:1861&#x2013;1863.</Citation></Reference><Reference><Citation>Cina SJ, Downs JC, Conradi SE. Hydrogen peroxide: a source of lethal oxygen embolism. Case report and review of the literature. Am J Forensic Med Pathol. 1994;15:44&#x2013;50.</Citation></Reference><Reference><Citation>Despond O, Fiset P. Oxygen venous embolism after the use of hydrogen peroxide during lumbar discectomy. Can J Anaesth. 1997;44:410&#x2013;413.</Citation></Reference><Reference><Citation>Dubey PK, Singh AK. Venous oxygen embolism due to hydrogen peroxide irrigation during posterior fossa surgery. J Neurosurg Anesthesiol. 2000;12:54&#x2013;56.</Citation></Reference><Reference><Citation>Chua ME, Kim JK, Mendoza JS, et al. The evaluation of vesicoureteral reflux among children using contrast-enhanced ultrasound: a literature review. J Pediatr Urol. 2019;15:12&#x2013;17.</Citation></Reference><Reference><Citation>He Y, Wu H, Xiong R, et al. Intravasation affects the diagnostic image quality of transvaginal 4-dimensional hysterosalpingo-contrast sonography with SonoVue. J Ultrasound Med. 2019;38:2169&#x2013;2180.</Citation></Reference><Reference><Citation>Lu Y, Liu B, Zheng Y, et al. Application of real-time three-dimensional contrast-enhanced ultrasound using SonoVue for the evaluation of focal liver lesions: a prospective single-center study. Am J Transl Res. 2018;10:1469&#x2013;1480.</Citation></Reference><Reference><Citation>Chew SS, Yang JL, Newstead GL, Douglas PR. Anal fistula: Levovist-enhanced endoanal ultrasound: a pilot study. Dis Colon Rectum. 2003;46:377&#x2013;384.</Citation></Reference><Reference><Citation>Shang Y, Xie X, Luo Y, et al. Safety findings after intravenous administration of sulfur hexafluoride microbubbles to 463,434 examinations at 24 centers. Eur Radiol. 2023;33:988&#x2013;995.</Citation></Reference><Reference><Citation>Poen AC, Felt-Bersma RJ, Eijsbouts QA, Cuesta MA, Meuwissen SG. Hydrogen peroxide-enhanced transanal ultrasound in the assessment of fistula-in-ano. Dis Colon Rectum. 1998;41:1147&#x2013;1152.</Citation></Reference><Reference><Citation>Navarro-Luna A, Garcia-Domingo MI, Rius-Macias J, Marco-Molina C. Ultrasound study of anal fistulas with hydrogen peroxide enhancement. Dis Colon Rectum. 2004;47:108&#x2013;114.</Citation></Reference><Reference><Citation>West RL, Zimmerman DD, Dwarkasing S, et al. Prospective comparison of hydrogen peroxide-enhanced three-dimensional endoanal ultrasonography and endoanal magnetic resonance imaging of perianal fistulas. Dis Colon Rectum. 2003;46:1407&#x2013;1415.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38830268</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Effect of Sublay Preventive Mesh for Terminal Colostomy on Symptoms and Quality of Life in Patients With Parastomal Hernia: A Post Hoc Analysis of the GRECCAR 7 Cohort.</ArticleTitle><Pagination><StartPage>1210</StartPage><EndPage>1216</EndPage><MedlinePgn>1210-1216</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000003257</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent randomized clinical trials and meta-analyses confirm that the use of a prophylactic mesh does not significantly reduce the parastomal hernia rate. Data about the benefits of these meshes concerning the symptoms of parastomal hernia are lacking in the existing literature.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to perform a post hoc analysis of the patients presenting parastomal hernia from the GRECCAR 7 (Groupe de recherche sur la chirurgie du cancer du rectum) randomized clinical trials cohort on whether the presence or the absence of the mesh influenced the symptoms, the quality of life, and complications of patients with parastomal hernias.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">We studied the parastomal hernia-related symptoms among the 2 groups of the GRECCAR 7 randomized clinical trial, with or without prophylactic mesh at the time of the index surgery.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Data were retrospectively extracted and analyzed from the GRECCAR 7 database.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients diagnosed with a parastomal hernia during the 2 years of the GRECCAR 7 study.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Several prospectively collected data about the symptoms were studied among this population. We also studied the average interval between parastomal hernia repair surgery and both index surgery and diagnosis of parastomal hernia.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 199 patients included in the GRECCAR study, 36 patients (35.6%) in the nonmesh group and 33 patients (33.7%) in the mesh group were diagnosed with clinical and/or radiological parastomal hernia at 2-year follow-up, without a statistically significant difference ( p = 0.89). None of the studied symptoms showed any statistically significant difference between the groups.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">This study relies on a relatively small number of patients, and although data were prospectively collected, we lacked some details about the categorization of parastomal hernias.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We believe that the use of a prosthetic mesh in a sublay position to prevent parastomal hernia in terminal end colostomy patients should no longer be recommended. See Video Abstract .</AbstractText><AbstractText Label="EFECTO DE LA MALLA PREVENTIVA RETROMUSCULAR PARA COLOSTOMA TERMINAL CON RESPECTO A LOS SNTOMAS Y LA CALIDAD DE VIDA EN PACIENTES CON HERNIA PARAESTOMAL UN ANLISIS POSTHOC DE LA COHORTE GRECCAR" NlmCategory="UNASSIGNED">ANTECEDENTES:Los recientes metaan&#xe1;lisis y ensayos cl&#xed;nicos aleatorizados confirman que el uso de una malla profil&#xe1;ctica no reduce significativamente la tasa de hernia paraestomal. En la literatura existente faltan datos sobre los beneficios de estas mallas en relaci&#xf3;n con los s&#xed;ntomas de la hernia paraestomal.OBJETIVO:El objetivo de este estudio fue realizar un an&#xe1;lisis post-hoc de los pacientes que presentaron hernia paraestomal de la cohorte de 7 ensayos cl&#xed;nicos aleatorizados GRECCAR sobre si la presencia o ausencia de la malla influy&#xf3; en los s&#xed;ntomas, la calidad de vida y las complicaciones de los pacientes con hernias paraestomales.DISE&#xd1;O:Estudiamos los s&#xed;ntomas relacionados con la hernia paraestomal entre los dos grupos del ensayo cl&#xed;nico aleatorizado GRECCAR 7, con o sin malla profil&#xe1;ctica en el momento de la cirug&#xed;a &#xed;ndice.AJUSTES:Los datos fueron extra&#xed;dos y analizados de manera retrospectiva de la base de datos GRECCAR 7.PACIENTES:Pacientes diagnosticados con hernia paraestomal durante los dos a&#xf1;os del estudio GRECCAR 7.PRINCIPALES MEDIDAS DE RESULTADO:Se estudiaron varios datos recopilados de manera prospectiva sobre los s&#xed;ntomas en esta poblaci&#xf3;n. Tambi&#xe9;n estudiamos el intervalo promedio entre la cirug&#xed;a reparadora de la hernia paraestomal as&#xed; como tambi&#xe9;n la cirug&#xed;a &#xed;ndice como el diagn&#xf3;stico de la hernia paraestomal.RESULTADOS:De entre los 199 pacientes incluidos en el estudio GRECCAR, 36 pacientes (35,6%) fueron diagnosticados con hernia paraestomal de manera cl&#xed;nica y/o radiol&#xf3;gica en el grupo sin malla a los 2 a&#xf1;os de seguimiento y 33 (33,7%) en el grupo con malla, sin diferencia estad&#xed;sticamente significativa ( p = 0,89). Ninguno de los s&#xed;ntomas estudiados mostr&#xf3; diferencias estad&#xed;sticamente significativas entre los grupos.LIMITACIONES:Este estudio se basa en un n&#xfa;mero relativamente peque&#xf1;o de pacientes y, aunque los datos fueron recopilados de forma prospectiva, nos faltaron algunos detalles sobre la categorizaci&#xf3;n de las hernias paraestomales.CONCLUSIONES:Creemos que ya no se debe recomendar el uso de una malla prot&#xe9;sica en posici&#xf3;n retromuscular para prevenir la hernia paraestomal en pacientes con colostom&#xed;a terminal. (Traducci&#xf3;n-Dr. Osvaldo Gauto ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bertrand</LastName><ForeName>Martin M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, CHU N&#xee;mes, Univ Montpellier, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Theuil</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, CHU N&#xee;mes, Univ Montpellier, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demattei</LastName><ForeName>Christophe</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, Public Health and Innovation in Methodology, CHU N&#xee;mes, Univ Montpellier, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prudhomme</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Digestive Surgery, CHU N&#xee;mes, Univ Montpellier, N&#xee;mes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>GRECCAR Group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013526" MajorTopicYN="Y">Surgical Mesh</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003125" MajorTopicYN="Y">Colostomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069290" MajorTopicYN="N">Incisional Hernia</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054047" MajorTopicYN="N">Surgical Stomas</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006555" MajorTopicYN="N">Hernia, Ventral</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>9</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>3</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>3</Day><Hour>17</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38830268</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000003257</ArticleId><ArticleId IdType="pii">00003453-202409000-00016</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carne P, Robertson G, Frizelle F. Parastomal hernia. Br J Surg. 2003;90:1306&#x2013;1307.</Citation></Reference><Reference><Citation>National Bowel Cancer Audit. Annual report 2021. An audit of the care received by people with bowel cancer in England and Wales. https://www.nboca.org.uk/content/uploads/2022/02/NBOCA-2021-AR-Final.pdf . Accessed August 31, 2023.</Citation></Reference><Reference><Citation>Glasgow SC, Dharmarajan S. Parastomal hernia: avoidance and treatment in the 21st century. Clin Colon Rectal Surg. 2016;29:277&#x2013;284.</Citation></Reference><Reference><Citation>Londono-Schimmer E, Leong A, Phillips R. Life table analysis of stomal complications following colostomy. Dis Colon Rectum. 1994;37:916&#x2013;920.</Citation></Reference><Reference><Citation>Ripoche J, Basurko C, Fabbro-Perray P, Prudhomme M. Parastomal hernia. A study of the French federation of ostomy patients. J Visc Surg. 2011;148:e435&#x2013;e441.</Citation></Reference><Reference><Citation>Antoniou S, Agresta F, Alamino JG, et al. European Hernia Society guidelines on prevention and treatment of parastomal hernias. Hernia. 2018;22:183&#x2013;198.</Citation></Reference><Reference><Citation>ACPGBI Parastomal Hernia Group. Prevention and treatment of parastomal hernia: a position statement on behalf of the Association of Coloproctology of Great Britain and Ireland. Colorectal Dis. 2018;20(suppl 2):5&#x2013;19.</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence. Reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia. Interventional procedures guidance [IPG654]. https://www.nice.org.uk/guidance/ipg654/resources/reinforcement-of-a-permanent-stoma-with-a-synthetic-or-biological-mesh-to-prevent-a-parastomal-hernia-pdf-1899874164041413 . Accessed August 31, 2023.</Citation></Reference><Reference><Citation>Aslam M, Rubio-Perez I, Smart N, Singh B; Committee ESoCE. A survey on practices for parastomal hernia prevention and repair among ESCP surgeons. Hernia. 2019;23:825&#x2013;828.</Citation></Reference><Reference><Citation>Prudhomme M, Rullier E, Lakkis Z, et al.; GRECCAR research group. End colostomy with or without mesh to prevent a parastomal hernia (GRECCAR 7): a prospective, randomized, double blinded, multicentre trial. Ann Surg. 2021;274:928&#x2013;934.</Citation></Reference><Reference><Citation>Odensten C, Strig&#xe5;rd K, Ruteg&#xe5;rd J, et al. Use of prophylactic mesh when creating a colostomy does not prevent parastomal hernia: a randomized controlled trial&#x2014;STOMAMESH. Ann Surg. 2019;269:427&#x2013;431.</Citation></Reference><Reference><Citation>Prudhomme M, Fabbro-Peray P, Rullier E, Occean BV, Bertrand MM. Meta-analysis and systematic review of the use of a prosthetic mesh for prevention of parastomal hernia. Ann Surg. 2021;274:20&#x2013;28.</Citation></Reference><Reference><Citation>Serra-Aracil X, Bombardo-Junca J, Moreno-Matias J, et al. Randomized, controlled, prospective trial of the use of a mesh to prevent parastomal hernia. Ann Surg. 2009;249:583&#x2013;587.</Citation></Reference><Reference><Citation>Lambrecht JR, Larsen SG, Reiertsen O, Vaktskjold A, Julsrud L, Flatmark K. Prophylactic mesh at end-colostomy construction reduces parastomal hernia rate: a randomized trial. Colorectal Dis. 2015;17:O191&#x2013;O197.</Citation></Reference><Reference><Citation>L&#xf3;pez-Cano M, Lozoya-Trujillo R, Quiroga S, et al. Use of a prosthetic mesh to prevent parastomal hernia during laparoscopic abdominoperineal resection: a randomized controlled trial. Hernia. 2012;16:661&#x2013;667.</Citation></Reference><Reference><Citation>L&#xf3;pez-Cano M, Serra-Aracils X, Mora L, et al. Preventing parastomal hernia using a modified Sugarbaker technique with composite mesh during laparoscopic abdominoperineal resection. Ann Surg. 2016;264:923&#x2013;928.</Citation></Reference><Reference><Citation>J&#xe4;nes A, Cengiz Y, Israelsson LA. Randomized clinical trial of the use of a prosthetic mesh to prevent parastomal hernia. Br J Surg. 2004;91:280&#x2013;282.</Citation></Reference><Reference><Citation>Fleshman JW, Beck DE, Hyman N, Wexner SD, Bauer J, George V; PRISM Study Group. A prospective, multicenter, randomized, controlled study of non-cross-linked porcine acellular dermal matrix fascial sublay for parastomal reinforcement in patients undergoing surgery for permanent abdominal wall ostomies. Dis Colon Rectum. 2014;57:623&#x2013;631.</Citation></Reference><Reference><Citation>Vierimaa M, Klintrup K, Biancari F, et al. Prospective, randomized study on the use of a prosthetic mesh for prevention of parastomal hernia of permanent colostomy. Dis Colon Rectum. 2015;58:943&#x2013;949.</Citation></Reference><Reference><Citation>M&#xe4;k&#xe4;r&#xe4;inen-Uhlb&#xe4;ck EJ, Klintrup KH, Vierimaa MT, et al. Prospective, randomized study on the use of prosthetic mesh to prevent a parastomal hernia in a permanent colostomy: results of a long-term follow-up. Dis Colon Rectum. 2020;63:678&#x2013;684.</Citation></Reference><Reference><Citation>Rajaretnam N, Smart NJ. To mesh or not to mesh&#x2014;the known unknowns of preventing parastomal hernias. Br J Surg. 2022;109:1&#x2013;2.</Citation></Reference><Reference><Citation>Prudhomme M, Alline M, Chauvat J, Fabbro-Perray P, Ripoche J, Bertrand MM; French Research Group of Rectal Cancer Surgery (GRECCAR). Primary prevention of peristomial hernias via parietal prostheses: a randomized, multicentric study (GRECCAR 7 trial). Dig Liver Dis. 2016;48:812&#x2013;816.</Citation></Reference><Reference><Citation>Prieto L, Thorsen H, Juul K. Development and validation of a quality of life questionnaire for patients with colostomy or ileostomy. Health Qual Life Outcomes. 2005;3:1&#x2013;10.</Citation></Reference><Reference><Citation>Marinez AC, Bock D, Carlsson E, et al. Stoma-related complications: a report from the Stoma-Const randomized controlled trial. Colorectal Dis. 2021;23:1091&#x2013;1101.</Citation></Reference><Reference><Citation>Marinez AC, Bock D, Erestam S, et al. Methods of colostomy construction: no effect on parastomal hernia rate: results from stoma-const&#x2014;a randomized controlled trial. Ann Surg. 2021;273:640&#x2013;647.</Citation></Reference><Reference><Citation>N&#xe4;verlo S, Gunnarsson U, Strig&#xe5;rd K, N&#xe4;svall P. Quality of life after end colostomy without mesh and with prophylactic synthetic mesh in sublay position: one-year results of the STOMAMESH trial. Int J Colorectal Dis. 2019;34:1591&#x2013;1599.</Citation></Reference><Reference><Citation>Brandsma H-T, Hansson BM, Aufenacker TJ, et al.; Dutch Prevent Study group. Prophylactic mesh placement during formation of an end-colostomy reduces the rate of parastomal hernia. Ann Surg. 2017;265:663&#x2013;669.</Citation></Reference><Reference><Citation>Conde-Mu&#xed;&#xf1;o R, D&#xed;ez JL, Mart&#xed;nez A, Huertas F, Segura I, Palma P. Preventing parastomal hernias with systematic intraperitoneal specifically designed mesh. BMC Surg. 2017;17:41.</Citation></Reference><Reference><Citation>Luo J, Singh D, Zhang F, et al. Comparison of the extraperitoneal and transperitoneal routes for permanent colostomy: a meta-analysis with RCTs and systematic review. World J Surg Oncol. 2022;20:82.</Citation></Reference><Reference><Citation>M&#xe4;k&#xe4;r&#xe4;inen-Uhlb&#xe4;ck E, Wiik H, K&#xf6;ssi J, Nikberg M, Ohtonen P, Rautio T. Chimney Trial: study protocol for a randomized controlled trial. Trials. 2019;20:652.</Citation></Reference><Reference><Citation>Liu Y, Fu X, Chen H, Yao Q. Surgical strategies for recurrent parastomal hernia after a primary repair with a Dynamesh(&#xae;) IPST mesh. Hernia. 2023;27:617&#x2013;621.</Citation></Reference><Reference><Citation>Chapman SJ, Wood B, Drake TM, Young N, Jayne DG. Systematic review and meta-analysis of prophylactic mesh during primary stoma formation to prevent parastomal hernia. Dis Colon Rectum. 2017;60:107&#x2013;115.</Citation></Reference><Reference><Citation>Hansson BM, Slater NJ, van der Velden AS, et al. Surgical techniques for parastomal hernia repair: a systematic review of the literature. Ann Surg. 2012;255:685&#x2013;695.</Citation></Reference><Reference><Citation>PROPHER Study Collaborating Group. The PROPHER Study: patient reported outcomes after parastomal hernia treatment&#x2014;a prospective international cohort study. Colorectal Dis. 2024;26:554&#x2013;563.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38011191</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2448-5667</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>Suppl 2</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>18</Day></PubDate></JournalIssue><Title>Revista medica del Instituto Mexicano del Seguro Social</Title><ISOAbbreviation>Rev Med Inst Mex Seguro Soc</ISOAbbreviation></Journal><ArticleTitle>[Prenatal diagnosis of placenta acretta by ultrasound and its histopathological association].</ArticleTitle><Pagination><StartPage>S96</StartPage><EndPage>S102</EndPage><MedlinePgn>S96-S102</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Anomalous adhesions of the placenta, known as placenta accreta and its variants, are the cause of obstetric hemorrhages that put the pregnant woman at risk. Accretism is strongly associated with a history of uterine surgery (cesarean section, myomectomy, curettage), as well as ultrasonographic signs, such as the presence and size of placental lacunae, loss of the placenta/bladder interface, location on the anterior face of the placenta, and presence of Doppler flow; these markers can be assessed by prenatal ultrasound.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To analyze the association of prenatal diagnosis of placenta accreta by ultrasound with the histopathological result using the Tovbin index.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="UNASSIGNED">Observational, cross-sectional and analytical study. 63 patients who had placenta accreta data by ultrasound measured with the Tovbin index and by means of the histopathological result obtained from the platform of the Mexican Institute for Social Security (IMSS) were included. The association between the two studies with the presence of placenta accreta was analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">63 patients were analyzed; the Tovbin index was positive in 89% of the patients with a diagnosis of placenta accreta confirmed by histopathology. Both the Tovbin index and the histopathology report showed a statistically significant association with a p value of 0.04 for the diagnosis of placenta accreta.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The Tovbin index as an ultrasonographic prenatal diagnosis of placenta accreta has a statistically significant association with histopathology diagnosis.</AbstractText><CopyrightInformation>Licencia CC 4.0 (BY-NC-ND) &#xa9; 2023 Revista M&#xe9;dica del Instituto Mexicano del Seguro Social.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zapien-Terrones</LastName><ForeName>Braulio C&#xe9;sar</ForeName><Initials>BC</Initials><Identifier Source="ORCID">0000-0003-2968-7742</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional del Baj&#xed;o, Hospital de Gineco Pediatr&#xed;a No. 48, Direcci&#xf3;n de Educaci&#xf3;n e Investigaci&#xf3;n en Salud. Le&#xf3;n, Guanajuato, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naves-S&#xe1;nchez</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9664-3902</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional del Baj&#xed;o, Hospital de Gineco Pediatr&#xed;a No. 48, Servicio de Ginecolog&#xed;a y Obstetricia. Le&#xf3;n, Guanajuato, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sosa-Bustamante</LastName><ForeName>Gloria Patricia</ForeName><Initials>GP</Initials><Identifier Source="ORCID">0000-0002-8460-4965</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional del Baj&#xed;o, Hospital de Gineco Pediatr&#xed;a No. 48, Direcci&#xf3;n de Educaci&#xf3;n e Investigaci&#xf3;n en Salud. Le&#xf3;n, Guanajuato, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez</LastName><ForeName>Alma Patricia</ForeName><Initials>AP</Initials><Identifier Source="ORCID">0000-0002-3401-7519</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional del Baj&#xed;o, Hospital de Gineco Pediatr&#xed;a No. 48, Direcci&#xf3;n de Educaci&#xf3;n e Investigaci&#xf3;n en Salud. Le&#xf3;n, Guanajuato, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paque-Bautista</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-2658-0491</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional del Baj&#xed;o, Hospital de Gineco Pediatr&#xed;a No. 48, Direcci&#xf3;n de Educaci&#xf3;n e Investigaci&#xf3;n en Salud. Le&#xf3;n, Guanajuato, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luna-Anguiano</LastName><ForeName>Jos&#xe9; Luis Felipe</ForeName><Initials>JLF</Initials><Identifier Source="ORCID">0000-0003-3739-8334</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional del Baj&#xed;o, Hospital de Gineco Pediatr&#xed;a No. 48, Direcci&#xf3;n General. Le&#xf3;n, Guanajuato, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peralta-Cort&#xe1;zar</LastName><ForeName>Catalina</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-8905-9863</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional del Baj&#xed;o, Hospital de Gineco Pediatr&#xed;a No. 48, Direcci&#xf3;n de Pediatr&#xed;a. Le&#xf3;n, Guanajuato, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><VernacularTitle>Diagn&#xf3;stico prenatal de acretismo placentario por ultrasonido y su asociaci&#xf3;n histopatol&#xf3;gica.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Rev Med Inst Mex Seguro Soc</MedlineTA><NlmUniqueID>101243727</NlmUniqueID><ISSNLinking>0443-5117</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010920" MajorTopicYN="Y">Placenta</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010921" MajorTopicYN="Y">Placenta Accreta</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002585" MajorTopicYN="N">Cesarean Section</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016216" MajorTopicYN="N">Ultrasonography, Prenatal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011296" MajorTopicYN="N">Prenatal Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="INTRODUCCI&#xd3;N" NlmCategory="UNASSIGNED">las adherencias an&#xf3;malas de la placenta, conocidas como acretismo, y sus variantes son causa de hemorragias obst&#xe9;tricas que ponen en riesgo a la gestante. El acretismo se asocia firmemente con antecedentes de cirug&#xed;as uterinas (ces&#xe1;rea, miomectom&#xed;a, legrados), as&#xed; como con signos ultrasonogr&#xe1;ficos como presencia y tama&#xf1;o de lagunas placentarias, p&#xe9;rdida de la interfaz placenta/vejiga, localizaci&#xf3;n en cara anterior de la placenta y presencia de flujo Doppler; estos marcadores pueden ser valorados mediante ecograf&#xed;a prenatal.</AbstractText><AbstractText Label="OBJETIVO" NlmCategory="UNASSIGNED">analizar la asociaci&#xf3;n de diagn&#xf3;stico prenatal de acretismo placentario por ultrasonido con el resultado histopatol&#xf3;gico utilizando el &#xcd;ndice de Tovbin.</AbstractText><AbstractText Label="MATERIAL Y M&#xc9;TODOS" NlmCategory="UNASSIGNED">estudio observacional, transversal y anal&#xed;tico. Se incluyeron 63 pacientes que ten&#xed;an datos de acretismo placentario por ultrasonido medido con el &#xcd;ndice de Tovbin y mediante el resultado histopatol&#xf3;gico obtenido de la plataforma del Instituto Mexicano del Seguro Social. Se analiz&#xf3; la asociaci&#xf3;n de ambos estudios con la presencia de acretismo placentario.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="UNASSIGNED">se analizaron 63 pacientes; el &#xcd;ndice de Tovbin fue positivo en un 89% de las pacientes con diagn&#xf3;stico de acretismo placentario confirmado por histopatolog&#xed;a. Tanto el &#xcd;ndice de Tovbin como el reporte de histopatolog&#xed;a mostraron una asociaci&#xf3;n estad&#xed;sticamente significativa con un valor de p de 0.04 para el diagn&#xf3;stico de acretismo placentario.</AbstractText><AbstractText Label="CONCLUSI&#xd3;N" NlmCategory="UNASSIGNED">el &#xcd;ndice de Tovbin como diagn&#xf3;stico prenatal ultrasonogr&#xe1;fico de acretismo placentario tiene asociaci&#xf3;n estad&#xed;sticamente significativa con el diagn&#xf3;stico de histopatolog&#xed;a.</AbstractText><CopyrightInformation>Licencia CC 4.0 (BY-NC-ND) &#xa9; 2023 Revista M&#xe9;dica del Instituto Mexicano del Seguro Social.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cesarean Section</Keyword><Keyword MajorTopicYN="N">Ces&#xe1;rea</Keyword><Keyword MajorTopicYN="N">Complicaciones del Embarazo</Keyword><Keyword MajorTopicYN="N">Cross-Sectional Studies</Keyword><Keyword MajorTopicYN="N">Estudios Transversales</Keyword><Keyword MajorTopicYN="N">Hemorragia Posparto</Keyword><Keyword MajorTopicYN="N">Maternal Mortality</Keyword><Keyword MajorTopicYN="N">Mortalidad Materna</Keyword><Keyword MajorTopicYN="N">Postpartum Hemorrhage</Keyword><Keyword MajorTopicYN="N">Pregnancy Complications</Keyword></KeywordList><CoiStatement>los autores han completado y enviado la forma traducida al espa&#xf1;ol de la declaraci&#xf3;n de conflictos potenciales de inter&#xe9;s del Comit&#xe9; Internacional de Editores de Revistas M&#xe9;dicas, y no fue reportado alguno que tuviera relaci&#xf3;n con este art&#xed;culo.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>29</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>27</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>27</Day><Hour>14</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38011191</ArticleId><ArticleId IdType="pmc">PMC10761192</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Silver RM, Barbour KD. Placenta accreta spectrum: accreta, increta, and percreta. Obstet Gynecol Clin North Am. 2015;42(2):381&#x2013;402. doi: 10.1016/j.ogc.2015.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ogc.2015.01.014</ArticleId><ArticleId IdType="pubmed">26002174</ArticleId></ArticleIdList></Reference><Reference><Citation>Mart&#xed;nez-Salazar GJ, Grimaldo-Valenzuela PM, V&#xe1;zquez-Pe&#xf1;a GG, Reyes-Segovia C, Torres-Luna G, Escudero-Lourdes GV. Operaci&#xf3;n ces&#xe1;rea. Una visi&#xf3;n hist&#xf3;rica, epidemiol&#xf3;gica y &#xe9;tica para disminuir su incidencia. Rev Med Inst Mex Seguro Soc. 2015;53(5):608&#x2013;615. Disponible en: http://revistamedica.imss.gob.mx/editorial/index.php/revista_medica/article/view/168/436 .</Citation><ArticleIdList><ArticleId IdType="pubmed">26383811</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick KE, Sellers S, Spark P, Kurinczuk JJ, Brocklehurst P, Knight M. The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study. BJOG. 2014;121(1):62&#x2013;70. doi: 10.1111/1471-0528.12405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1471-0528.12405</ArticleId><ArticleId IdType="pmc">PMC3906842</ArticleId><ArticleId IdType="pubmed">23924326</ArticleId></ArticleIdList></Reference><Reference><Citation>Jauniaux E, Collins S, Burton GJ. Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. Am J Obstet Gynecol. 2018;218(1):75&#x2013;87. doi: 10.1016/j.ajog.2017.05.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2017.05.067</ArticleId><ArticleId IdType="pubmed">28599899</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-de la Torre JI, Gonz&#xe1;lez-Cant&#xfa; G, Rodr&#xed;guez-Vald&#xe9;z A, Mujica-Torres A, Villa-Ponce D, Aguilar-Zamudio J. Acretismo placentario con abordaje predictivo y preventivo de hemorragia obst&#xe9;trica. Ginecol Obstet Mex. 2018;86(6):357&#x2013;367. doi: 10.24245/gom.v86i6.2034.</Citation><ArticleIdList><ArticleId IdType="doi">10.24245/gom.v86i6.2034</ArticleId></ArticleIdList></Reference><Reference><Citation>Silver RM, Branch DW. Placenta Accreta Spectrum. N Engl J Med. 2018;378(16):1529&#x2013;1536. doi: 10.1056/NEJMcp1709324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcp1709324</ArticleId><ArticleId IdType="pubmed">29669225</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram&#xed;rez-Cabrera JO, Zapata-D&#xed;az BM. Espectro de placenta acreta. Rev Peru Ginecol Obstet. 2020;66(1):49&#x2013;55. doi: 10.31403/rpgo.v66i2232.</Citation><ArticleIdList><ArticleId IdType="doi">10.31403/rpgo.v66i2232</ArticleId></ArticleIdList></Reference><Reference><Citation>Berhan Y, Urgie T. A Literature Review of Placenta Accreta Spectrum Disorder: The Place of Expectant Management in Ethiopian Setup. Ethiop J Health Sci. 2020;30(2):277&#x2013;292. doi: 10.4314/ejhs.v30i2.16.</Citation><ArticleIdList><ArticleId IdType="doi">10.4314/ejhs.v30i2.16</ArticleId><ArticleId IdType="pmc">PMC7060376</ArticleId><ArticleId IdType="pubmed">32165818</ArticleId></ArticleIdList></Reference><Reference><Citation>Sichitiu J, El-Tani Z, Mathevet P, Desseauve D. Conservative Surgical Management of Placenta Accreta Spectrum: A Pragmatic Approach. J Invest Surg. 2021;34(2):172&#x2013;180. doi: 10.1080/08941939.2019.1623956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08941939.2019.1623956</ArticleId><ArticleId IdType="pubmed">31429327</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Rosas R, Cruz-Cruz P, Torres-Arreola L. Hemorragia obst&#xe9;trica, causa de muerte materna. IMSS, 2011. Rev Med Inst Mex Seguro Soc. 50;(6):659&#x2013;664. Disponible en: http://revistamedica.imss.gob.mx/editorial/index.php/revista_medica/article/view/1105/1737 .</Citation><ArticleIdList><ArticleId IdType="pubmed">23331753</ArticleId></ArticleIdList></Reference><Reference><Citation>Dur&#xe1;n-Nah JJ, Sosa-Ek MV, Chac&#xf3;n-Hern&#xe1;ndez L. Perfil hemost&#xe1;tico en pacientes con y sin hemorragia obst&#xe9;trica posparto. Rev Med Inst Mex Seguro Soc. 2018;56(6):517&#x2013;524. Disponible en: http://revistamedica.imss.gob.mx/editorial/index.php/revista_medica/article/view/1430/3288 .</Citation><ArticleIdList><ArticleId IdType="pubmed">30889339</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehrabadi A, Hutcheon JA, Liu S, Bartholomew S, Kramer MS, Liston RM. Contribution of placenta accreta to the incidence of postpartum hemorrhage and severe postpartum hemorrhage. Obstet Gynecol. 2015;125(4):814&#x2013;821. doi: 10.1097/AOG.0000000000000722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AOG.0000000000000722</ArticleId><ArticleId IdType="pubmed">25751202</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinograd A, Wainstock T, Mazor M, Beer-Weisel R, Klaitman V, Dukler D. Placenta accreta is an independent risk factor for late pre-term birth and perinatal mortality. J Matern Fetal Neonatal Med. 2015;28(12):1381&#x2013;1387. doi: 10.3109/14767058.2014.955004.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/14767058.2014.955004</ArticleId><ArticleId IdType="pubmed">25142109</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailit JL, Grobman WA, Rice MM, Reddy UM, Wapner RJ, Varner MW. Morbidly adherent placenta treatments and outcomes. Obstet Gynecol. 2015;125(3):683&#x2013;689. doi: 10.1097/AOG.0000000000000680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/AOG.0000000000000680</ArticleId><ArticleId IdType="pmc">PMC4347990</ArticleId><ArticleId IdType="pubmed">25730233</ArticleId></ArticleIdList></Reference><Reference><Citation>Haghenbeck-Altamirano FJ, Leis-M&#xe1;rquez T, Ayala-Y&#xe1;&#xf1;ez R, Ju&#xe1;rez-Garc&#xed;a LC, Garc&#xed;a-Moreno C. Diagn&#xf3;stico antenatal de acretismo-percretismo placentario. Ginecol Obstet Mex. 2013;81(5):259&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">23819426</ArticleId></ArticleIdList></Reference><Reference><Citation>Tovbin J, Melcer Y, Shor S, Pekar-Zlotin M, Mendlovic S, Svirsky R. Prediction of morbidly adherent placenta using a scoring system. Ultrasound Obstet Gynecol. 2016;48(4):504&#x2013;510. doi: 10.1002/uog.15813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/uog.15813</ArticleId><ArticleId IdType="pubmed">26574157</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujisaki M, Furukawa S, Maki Y, Oohashi M, Doi K, Sameshima H. Maternal Morbidity in Women with Placenta Previa Managed with Prediction of Morbidly Adherent Placenta by Ultrasonography. J Pregnancy. 2017;2017 doi: 10.1155/2017/8318751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/8318751</ArticleId><ArticleId IdType="pmc">PMC5421082</ArticleId><ArticleId IdType="pubmed">28523191</ArticleId></ArticleIdList></Reference><Reference><Citation>Jauniaux E, Collins SL, Jurkovic D, Burton GJ. Accreta placentation: a systematic review of prenatal ultrasound imaging and grading of villous invasiveness. Am J Obstet Gynecol. 2016;215(6):712&#x2013;721. doi: 10.1016/j.ajog.2016.07.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2016.07.044</ArticleId><ArticleId IdType="pubmed">27473003</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandoval Garc&#xed;a-Traves&#xed; FA, Reyes-Hern&#xe1;ndez MU, Sandoval-Barajas D, Morales-Hern&#xe1;ndez S, Tovar-Galv&#xe1;n V, Hinojosa-Cruz JC. Placenta praevia: perinatal outcomes in the experience of a third level medical unit. Cir Cir. 2019;87(6):667&#x2013;673. doi: 10.24875/CIRU.19000861.</Citation><ArticleIdList><ArticleId IdType="doi">10.24875/CIRU.19000861</ArticleId><ArticleId IdType="pubmed">31631190</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu&#xf1;iz Rizo ME, &#xc1;lvarez Ponce VA, Felipe Cuti&#xe9; W. Acretismo placentario. Rev Cubana Obstet Ginecol. 2015;41(2):190&#x2013;196. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0138-600X2015000200012&amp;lng=es .</Citation></Reference><Reference><Citation>Erfani H, Fox KA, Clark SL, Rac M, Rocky Hui SK, Rezaei A. Maternal outcomes in unexpected placenta accreta spectrum disorders: single-center experience with a multidisciplinary team. Am J Obstet Gynecol. 2019;221(4):337.e1&#x2013;337.e5. doi: 10.1016/j.ajog.2019.05.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2019.05.035</ArticleId><ArticleId IdType="pmc">PMC8651298</ArticleId><ArticleId IdType="pubmed">31173748</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurn L, Lindqvist PG, Jakobsson M, Colmorn LB, Klungsoyr K, Bjarnadottir RI. Abnormally invasive placenta&#x2014;prevalence, risk factors and antenatal suspicion: results from a large population-based pregnancy cohort study in the Nordic countries. BJOG. 2016;123:1348&#x2013;1355. doi: 10.1111/1471-0528.13547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1471-0528.13547</ArticleId><ArticleId IdType="pubmed">26227006</ArticleId></ArticleIdList></Reference><Reference><Citation>Fishman SG, Chasen ST, Maheshwari B. Risk factors for preterm delivery with placenta previa. J Perinat Med. 2011;40(1):39&#x2013;42. doi: 10.1515/JPM.2011.125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/JPM.2011.125</ArticleId><ArticleId IdType="pubmed">22085154</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani G, Cali G, Acharya G, Trich IT, Palacios-Jaraquemada J, Familiari A. Diagnostic accuracy of ultrasound in detecting the severity of abnormally invasive placentation: a systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2018;97(1):25&#x2013;37. doi: 10.1111/aogs.13238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aogs.13238</ArticleId><ArticleId IdType="pubmed">28963728</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal S, Agarwal A, Chandak S. Role of placenta accreta index in prediction of morbidly adherent placenta: A reliability study. Ultrasound. 2021;29(2):92&#x2013;99. doi: 10.1177/1742271X20959742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1742271X20959742</ArticleId><ArticleId IdType="pmc">PMC8083140</ArticleId><ArticleId IdType="pubmed">33995555</ArticleId></ArticleIdList></Reference><Reference><Citation>Tikkanen M, Paavonen J, Loukovaara M, Stefanovic V. Antenatal diagnosis of placenta accreta leads to reduced blood loss. Acta Obstet Gynecol Scand. 2011;90(10):1140&#x2013;1146. doi: 10.1111/j.1600-0412.2011.01147.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0412.2011.01147.x</ArticleId><ArticleId IdType="pubmed">21488840</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37934876</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2448-5667</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><Issue>Suppl 3</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>02</Day></PubDate></JournalIssue><Title>Revista medica del Instituto Mexicano del Seguro Social</Title><ISOAbbreviation>Rev Med Inst Mex Seguro Soc</ISOAbbreviation></Journal><ArticleTitle>[Interobserver agreement in the diagnosis of bladder outlet obstruction in women].</ArticleTitle><Pagination><StartPage>S422</StartPage><EndPage>S428</EndPage><MedlinePgn>S422-S428</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5281/zenodo.8319775</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The diagnosis of bladder outlet obstruction (BOO) in women is a challenge for functional urology. In Mexico there are few data that report the prevalence of OTSV in women, being up to 24% in a group of patients.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">The aim of this study is to compare six different definitions of bladder outlet obstruction and evaluate the interobserver agreement in an educational setting.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="UNASSIGNED">Urodynamic studies (UDS) of women with and without diagnosis of BOO were retrospectively assesed. Farrar, Chassagne, Lemack, Defreitas, Blavais and Groutz, Solomon-Greenwell definitions were evaluated. All UDS were independently reviewed by 5 observers. The easiest, the hardest and the fastest were chosen. Interobserver agreement to classify the patients as obstructed was assessed by kappa reliability statistical analysis. We classified the type of mistakes the participants made; error of interpretation and miscalculation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 28 urodynamic studies were reviewed. All observers had a substantial agreement (0.64-0.78) to classify BOO using all but Lemack and Solomon-Greenwell definitions. A total 120 errors from 840 responses were found; 45.8% errors of interpretation of UDS and 54.1% miscalculation of the equation. Finally, all the participants chose the Solomon-Greenwell was the most difficult definition.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Chassagne, Defreitas and Farrar definitions proved substantial interobserver agreement. Solomon-Greenwell and Lemack&#xb4;s definitions had the highest number of pitfalls and the lowest level of agreement.</AbstractText><CopyrightInformation>Licencia CC 4.0 (BY-NC-ND) &#xa9; 2023 Revista M&#xe9;dica del Instituto Mexicano del Seguro Social.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vidal-Brandt</LastName><ForeName>Ana Silvia</ForeName><Initials>AS</Initials><Identifier Source="ORCID">0000-0002-0946-7374</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional Siglo XXI, Hospital de Especialidades, Servicio de Urolog&#xed;a. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castro-N&#xfa;&#xf1;ez</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-1708-3159</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional Siglo XXI, Hospital de Especialidades, Servicio de Urolog&#xed;a. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noyola-&#xc1;vila</LastName><ForeName>Immer</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0001-8370-5898</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional Siglo XXI, Hospital de Especialidades, Servicio de Urolog&#xed;a. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Mu&#xf1;oz</LastName><ForeName>Uziel</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0002-4570-3186</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional Siglo XXI, Hospital de Especialidades, Servicio de Urolog&#xed;a. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maldonado-Alcaraz</LastName><ForeName>Efra&#xed;n</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-4308-2662</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional Siglo XXI, Hospital de Especialidades, Servicio de Urolog&#xed;a. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreno-Palacios</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-9994-4922</Identifier><AffiliationInfo><Affiliation>Instituto Mexicano del Seguro Social, Centro M&#xe9;dico Nacional Siglo XXI, Hospital de Especialidades, Servicio de Urolog&#xed;a. Ciudad de M&#xe9;xico, M&#xe9;xico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Variabilidad interobservador en el diagn&#xf3;stico de obstrucci&#xf3;n del tracto de salida vesical en mujeres.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Mexico</Country><MedlineTA>Rev Med Inst Mex Seguro Soc</MedlineTA><NlmUniqueID>101243727</NlmUniqueID><ISSNLinking>0443-5117</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001748" MajorTopicYN="Y">Urinary Bladder Neck Obstruction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015588" MajorTopicYN="N">Observer Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N" Type="Geographic">Mexico</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="INTRODUCCI&#xd3;N" NlmCategory="UNASSIGNED">el diagn&#xf3;stico de obstrucci&#xf3;n de tracto de salida vesical (OTSV) en mujeres supone un reto para la urolog&#xed;a funcional. En M&#xe9;xico existen pocos datos que reporten la prevalencia de OTSV en mujeres, siendo de hasta el 24% en un grupo de pacientes.</AbstractText><AbstractText Label="OBJETIVO" NlmCategory="UNASSIGNED">comparar seis definiciones diferentes de obstrucci&#xf3;n de tracto de salida vesical (OTSV) en mujeres y evaluar la concordancia entre observadores en un entorno educativo.</AbstractText><AbstractText Label="MATERIAL Y M&#xc9;TODOS" NlmCategory="UNASSIGNED">evaluaci&#xf3;n retrospectiva de estudios urodin&#xe1;micos de mujeres con y sin diagn&#xf3;stico de OTSV. Se evaluaron las definiciones de Farrar, Chassagne, Lemack, Defreitas, Blavais y Groutz y Solomon-Greenwell. A todos los participantes se les brind&#xf3; un taller te&#xf3;rico-pr&#xe1;ctico para analizar los estudios urodin&#xe1;micos en su fase de flujo-presi&#xf3;n y diagnosticar la OTSV. Los estudios urodin&#xe1;micos fueron revisados de forma independiente por cinco observadores. La concordancia interobservador para clasificar a los pacientes como obstruidos se evalu&#xf3; mediante an&#xe1;lisis estad&#xed;stico de confiabilidad kappa. Se clasific&#xf3; el tipo de errores que cometieron los participantes, error de interpretaci&#xf3;n de estudios urodin&#xe1;micos y error de c&#xe1;lculo en los criterios.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="UNASSIGNED">se revisaron en total 28 estudios urodin&#xe1;micos. Todos los observadores tuvieron una concordancia buena de (0.64-0.78) para clasificar OTSV usando todas las definiciones excepto las de Lemack y Solomon-Greenwell. Se encontraron un total de 120 errores de 840 respuestas, 45.8% errores de interpretaci&#xf3;n y 54.1% error de c&#xe1;lculo de la ecuaci&#xf3;n. Los participantes eligieron la definici&#xf3;n de Solomon-Greenwell, la m&#xe1;s dif&#xed;cil.</AbstractText><AbstractText Label="CONCLUSI&#xd3;N" NlmCategory="UNASSIGNED">las definiciones de Chassagne, Defreitas y Farrar demostraron una concordancia sustancial entre observadores. Las definiciones de Solomon-Greenwell y Lemack tuvieron el mayor grado de dificultad y el menor nivel de acuerdo.</AbstractText><CopyrightInformation>Licencia CC 4.0 (BY-NC-ND) &#xa9; 2023 Revista M&#xe9;dica del Instituto Mexicano del Seguro Social.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Concordance Analysis</Keyword><Keyword MajorTopicYN="N">Estudio de Concordancia</Keyword><Keyword MajorTopicYN="N">Mujeres</Keyword><Keyword MajorTopicYN="N">Trastornos Urinarios</Keyword><Keyword MajorTopicYN="N">Urinary Bladder</Keyword><Keyword MajorTopicYN="N">Urination Disorders</Keyword><Keyword MajorTopicYN="N">Vejiga Urinaria</Keyword><Keyword MajorTopicYN="N">Women</Keyword></KeywordList><CoiStatement>los autores han completado y enviado la forma traducida al espa&#xf1;ol de la declaraci&#xf3;n de conflictos potenciales de inter&#xe9;s del Comit&#xe9; Internacional de Editores de Revistas M&#xe9;dicas, y no fue reportado alguno que tuviera relaci&#xf3;n con este art&#xed;culo.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>7</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>7</Day><Hour>15</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37934876</ArticleId><ArticleId IdType="pmc">PMC10746333</ArticleId><ArticleId IdType="doi">10.5281/zenodo.8319775</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ruiz MIG. Prevalencia de disfunci&#xf3;n de vaciado vesical y hallazgos cl&#xed;nico-urodin&#xe1;micos en dos unidades uroginecol&#xf3;gicas. Ginecol Obstet M&#xc9;XICO. 2005</Citation><ArticleIdList><ArticleId IdType="pubmed">16579165</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang KH, Campi R, Arlandis S, et al. Diagnostic Tests for Female Bladder Outlet Obstruction: A Systematic Review from the European Association of Urology Non-neurogenic Female LUTS Guidelines Panel. Eur Urol Focus. 2022;8(4):1015&#x2013;1030. doi: 10.1016/j.euf.2021.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.euf.2021.09.003</ArticleId><ArticleId IdType="pubmed">34538750</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CD, Kuo HC, Yang SS. Diagnosis and Management of Bladder Outlet Obstruction in Women. Low Urin Tract Symptoms. 2016;8(1):30&#x2013;37. doi: 10.1111/luts.12094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/luts.12094</ArticleId><ArticleId IdType="pubmed">26789540</ArticleId></ArticleIdList></Reference><Reference><Citation>Groutz A, Blaivas JG, Fait G, Sassone AM, Chaikin DC, Gordon D. The significance of the American Urological Association symptom index score in the evaluation of women with bladder outlet obstruction. J Urol. 2000;163(1):207&#x2013;211.</Citation><ArticleIdList><ArticleId IdType="pubmed">10604349</ArticleId></ArticleIdList></Reference><Reference><Citation>Winters JC, Dmochowski RR, Goldman HB, et al. American Urological Association; Society of Urodynamics, Female Pelvic Medicine &amp; Urogenital Reconstruction. Urodynamic studies in adults: AUA/SUFU guideline. J Urol. 2012;188(6 Suppl):2464&#x2013;2472. doi: 10.1016/j.juro.2012.09.081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2012.09.081</ArticleId><ArticleId IdType="pubmed">23098783</ArticleId></ArticleIdList></Reference><Reference><Citation>Mai HC, Wu RC, Lin VC, Kuo WW, Wu CH. External validation of Solomon-Greenwell nomogram for female bladder outlet obstruction. Neurourol Urodyn. 2022;41(2):626&#x2013;632. doi: 10.1002/nau.24863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/nau.24863</ArticleId><ArticleId IdType="pubmed">34962312</ArticleId></ArticleIdList></Reference><Reference><Citation>Chassagne S, Bernier PA, Haab F, Roehrborn CG, Reisch JS, Zimmern PE. Proposed cutoff values to define bladder outlet obstruction in women. Urology. 1998;51(3):408&#x2013;411. doi: 10.1016/s0090-4295(97)00634-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0090-4295(97)00634-1</ArticleId><ArticleId IdType="pubmed">9510344</ArticleId></ArticleIdList></Reference><Reference><Citation>Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21(1):5&#x2013;26. doi: 10.1007/s00192-009-0976-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00192-009-0976-9</ArticleId><ArticleId IdType="pubmed">19937315</ArticleId></ArticleIdList></Reference><Reference><Citation>Panicker JN, Anding R, Arlandis S, et al. Do we understand voiding dysfunction in women? Current understanding and future perspectives: ICI-RS 2017. Neurourol Urodyn. 2018;37(S4):S75&#x2013;S85. doi: 10.1002/nau.23709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/nau.23709</ArticleId><ArticleId IdType="pubmed">30133794</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitti VW, Tu LM, Gitlin J. Diagnosing bladder outlet obstruction in women. J Urol. 1999;161(5):1535&#x2013;1540.</Citation><ArticleIdList><ArticleId IdType="pubmed">10210391</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrar DJ, Osborne JL, Stephenson TP, Whiteside CG, Weir J, Berry J, Milroy EJ, Warwick RT. A urodynamic view of bladder outflow obstruction in the female: factors influencing the results of treatment. Br J Urol. 1975;47(7):815&#x2013;822. doi: 10.1111/j.1464-410x.1975.tb04062.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1464-410x.1975.tb04062.x</ArticleId><ArticleId IdType="pubmed">1241332</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemack GE, Zimmern PE. Pressure flow analysis may aid in identifying women with outflow obstruction. J Urol. 2000;163(6):1823&#x2013;1828.</Citation><ArticleIdList><ArticleId IdType="pubmed">10799191</ArticleId></ArticleIdList></Reference><Reference><Citation>Defreitas GA, Zimmern PE, Lemack GE, Shariat SF. Refining diagnosis of anatomic female bladder outlet obstruction: comparison of pressure-flow study parameters in clinically obstructed women with those of normal controls. Urology. 2004;64(4):675&#x2013;679. doi: 10.1016/j.urology.2004.04.089. discussion 679-81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.urology.2004.04.089</ArticleId><ArticleId IdType="pubmed">15491697</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaivas JG, Groutz A. Bladder outlet obstruction nomogram for women with lower urinary tract symptomatology. Neurourol Urodyn. 2000;19(5):553&#x2013;564. doi: 10.1002/1520-6777(2000)19:5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1520-6777(2000)19:5</ArticleId><ArticleId IdType="pubmed">11002298</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon E, Yasmin H, Duffy M, Rashid T, Akinluyi E, Greenwell TJ. Developing and validating a new nomogram for diagnosing bladder outlet obstruction in women. Neurourol Urodyn. 2018;37(1):368&#x2013;378. doi: 10.1002/nau.23307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/nau.23307</ArticleId><ArticleId IdType="pubmed">28666055</ArticleId></ArticleIdList></Reference><Reference><Citation>Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">843571</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi YS, Kim JC, Lee KS, et al. Analysis of female voiding dysfunction: a prospective, multi-center study. Int Urol Nephrol. 2013;45(4):989&#x2013;994. doi: 10.1007/s11255-013-0475-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11255-013-0475-2</ArticleId><ArticleId IdType="pubmed">23722818</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanton SL, Ozsoy C, Hilton P. Voiding difficulties in the female: prevalence, clinical and urodynamic review. Obstet Gynecol. 1983;61(2):144&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pubmed">6823355</ArticleId></ArticleIdList></Reference><Reference><Citation>Chassagne S, Bernier PA, Haab F, Roehrborn CG, Reisch JS, Zimmern PE. Proposed cutoff values to define bladder outlet obstruction in women. Urology. 1998;51(3):408&#x2013;411. doi: 10.1016/s0090-4295(97)00634-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0090-4295(97)00634-1</ArticleId><ArticleId IdType="pubmed">9510344</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosier PFWM, Schaefer W, Lose G, et al. International Continence Society Good Urodynamic Practices and Terms 2016: Urodynamics, uroflowmetry, cystometry, and pressure-flow study. Neurourol Urodyn. 2017;36(5):1243&#x2013;1260. doi: 10.1002/nau.23124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/nau.23124</ArticleId><ArticleId IdType="pubmed">27917521</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindsay J, Solomon E, Nadeem M, et al. Treatment validation of the Solomon-Greenwell nomogram for female bladder outlet obstruction. Neurourol Urodyn. 2020;39(5):1371&#x2013;1377. doi: 10.1002/nau.24347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/nau.24347</ArticleId><ArticleId IdType="pubmed">32249980</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro NP, Noyola &#xc1;I, Maldonado AE, et al. Solomon-Greenwell as the most accurate nomogram for female bladder outlet obstruction. Revista Mexicana de Urolog&#xed;a. 2007;82(6):2022. doi: 10.48193/revistamexicanadeurologa.v82i6.873.</Citation><ArticleIdList><ArticleId IdType="doi">10.48193/revistamexicanadeurologa.v82i6.873</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers K, Apostolidis A, Constantinou C ICI-RS 2014. Recommendations for future development of contractility and obstruction nomograms for women. Neurourol Urodyn. 2016;35(2):307&#x2013;311. doi: 10.1002/nau.22776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/nau.22776</ArticleId><ArticleId IdType="pubmed">26872573</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivera CA, Castro NP, Serrano BE, et al. Nomograma de Zimmern como prueba diagn&#xf3;stica en mujeres con disfunci&#xf3;n del vaciamiento vesical y tratadas mediante esfinterotom&#xed;a anteromedial. Bol Col Mex Urol. 2021;36:1&#x2013;6. doi: 10.24245/bcmurol.6752.</Citation><ArticleIdList><ArticleId IdType="doi">10.24245/bcmurol.6752</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiteside JL, Hijaz A, Imrey PB, et al. Reliability and agreement of urodynamics interpretations in a female pelvic medicine center. Obstet Gynecol. 2006;108(2):315&#x2013;323. doi: 10.1097/01.AOG.0000227778.77189.2d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.AOG.0000227778.77189.2d</ArticleId><ArticleId IdType="pubmed">16880301</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmern P, Nager CW, Albo M, Fitzgerald MP, McDermott S Urinary Incontinence Treatment Network. Interrater reliability of filling cystometrogram interpretation in a multicenter study. J Urol. 2006;175(6):2174&#x2013;2177. doi: 10.1016/S0022-5347(06)00343-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5347(06)00343-0</ArticleId><ArticleId IdType="pubmed">16697832</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>